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ABSTRACT 
 
Cytokine Detection in EIAV-Infected Equine Monocyte-Derived Macrophages  
 Using Quantitative Real-Time Polymerase Chain Reaction. (December 2007) 
Charlotte Annette Allen, B.S., Lyon College 
Chair of Advisory Committee: Dr. Karen Russell 
 
The replication of equine infectious anemia virus (EIAV) in macrophages not 
only leads to cell death, but also to the induction of a variety of cytokines that may affect 
immune function.  Cytokine production may be responsible for the fever, anorexia, 
hemorrhages, lethargy or thrombocytopenia seen in the acute and chronic phases of 
equine infectious anemia (EIA).  The study of the equine immune system and 
inflammatory responses, by measuring cytokine expression, can provide important 
insight into disease pathogenesis in the horse.  We have extended studies of virulent and 
avirulent EIAV clones by examining the effects of Env proteins on cytokine expression 
in equine monocyte-derived macrophages (EMDM) using EIAV17, EIAV19, EIAV17SU, 
and EIAV17TM viruses.  In the current studies a set of quantitative real-time polymerase 
chain reaction (QPCR) assays for the equine cytokines IL-1α, IL-1β, IL-6, IL-8 and 
TNF-α were validated using QPCR primers and probes which were generated for the 
aforementioned equine genes.   
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NOMENCLATURE 
 
 
ACD        anticoagulant citrate dextrose  
AIDS               acquired immunodeficiency syndrome 
BIV       bovine immunodeficiency virus  
CA            capsid 
CAEV       caprine arthritis encephalitis virus  
Cf2Th       canine thymus  
CM           control media  
CPE          cytopathic effect 
Cpm             counts per minute 
Ct        threshold cycle 
CV       coefficient of variation 
ED                  equine dermis 
EIA            equine infectious anemia 
EIAV       equine infectious anemia virus 
ELR-1  equine lentivirus receptor-1 
EMDM      equine monocyte-derived macrophages 
Env  envelope 
FEK      fetal kidney cells 
FIV             feline immunodeficiency virus 
Gag   group-associated antigen 
Hpi                  hours post-infection  
HIV             human immunodeficiency virus 
IP3                  inositol 1,4,5 triphosphate   
L                 late 
LPS            lipopolysaccharide 
LTR           long terminal repeat 
 vii
MA            matrix 
MCP-1       monocyte chemoattractant protein 
MDBP  methylated DNA-binding protein site 
MEM α      minimum essential medium alpha 
mAb           monoclonal antibodies 
MVV             maedi-visna virus  
NC              nucleocapsid  
NX[S/T]     N-linked glycosylation sites 
PBMC        peripheral blood mononuclear cells 
PND  principal neutralizing domain 
Pol  polymerase  
PR  protease 
PU.1  purine-rich element 
QPCR        quantitative real-time polymerase chain reaction  
R                 repeat 
RAO           recurrent airway obstruction  
RRE            rev-response element 
RT              reverse transcriptase 
RT-cPCR   reverse transcription competitive chain reaction 
RT-PCR     reverse transcription polymerase chain reaction  
RPA           ribonuclease protection assay  
SCID               severe combined immunodeficiency 
SIV            simian immunodeficiency virus 
SU   surface 
TAR   trans-activation responsive 
TM  transmembrane  
U3  unique 3 end 
U5  unique 5 end 
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CHAPTER I 
INTRODUCTION 
1.1. EIAV classification 
Equine infectious anemia virus (EIAV), a lentivirus belonging to the family 
Retroviridae, affects horses, ponies, donkeys and mules.  The family gets its name from 
the fact that these viruses contain the reverse transcriptase (RT) enzyme which enables 
them to reverse the flow of genetic information, from RNA to DNA whereas the 
conventional flow of genomic information in most other living organisms is from DNA 
to RNA (Dahlberg, 1988).  Based on reverse transcriptase activity, genetic organization, 
serologic cross-reactivity and ultrastructure, EIAV is most closely related to maedi-visna 
virus (MVV) of sheep and caprine arthritis encephalitis virus (CAEV) of goats (Gonda, 
et al., 1978; Stephens et al., 1986; Kawajami et al., 1987; Montelaro et al., 1993).  EIAV 
is also related other nonhuman lentiviruses such as bovine immunodeficiency virus 
(BIV) and feline immunodeficiency virus (FIV). One major difference between EIAV 
and other lentiviruses is that EIAV does not encode a Vif protein (Oberste and Gonda, 
1992; Olsen, 2001; Navarro and Landau, 2004). EIAV is also distantly related to the two 
human immunodeficiency viruses (HIV-1 and HIV-2), which cause acquired 
immunodeficiency syndrome (AIDS) and the simian immunodeficiency virus (SIV) 
(Gonda, et al., 1978; Stephens et al., 1986; Kawajami et al., 1987; Montelaro et al., 
1993).  HIV and SIV are closely related to each other and differ from the other lenti- 
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viruses by the use of CD4 protein as receptor on lymphocytes and the absence of 
dUTPase (Olsen, 2001). 
1.2. EIAV morphology and genome organization  
EIAV is an enveloped RNA virus approximately 100 nm in diameter covered 
with surface “knobs” (Gonda, et al., 1978).  The structure of a mature EIAV virion 
consists of a conically shaped core containing viral RNA surrounded by an exterior lipid 
envelope that is derived from the host-cell membrane during budding (Gonda, et al., 
1978) (Fig.1.1, Fig.1.2).  
All retroviruses including EIAV contain three major genes: gag (group-
associated antigen), pol (polymerase), and env (envelope) (Fig. 1.3) (Olsen, 2001; 
Balvey et al., 2007).  EIAV gag encodes the capsid proteins, which include the 
membrane-interacting matrix (MA) p15, the capsid (CA) p26, and the RNA-binding 
nucleocapsid (NC) proteins p11 and p9 (Stephens et al., 1986; Hussain et al., 1988).  Pol 
encodes protease (PR), reverse transcriptase (RT), dUTPase and integrase (Leroux et al., 
2004).  Env encodes two glycoproteins, the surface glycoprotein (SU) and the 
transmembrane glycoprotein (TM) (Leroux et al., 2004).  The EIAV genome also 
contains additional open reading frames encoding the Tat, Rev, and S2 proteins (Fig. 
1.3) (Leroux et al., 2004).   
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Fig. 1.1. Electron micrograph of thin sections of equine macrophages infected with EIAV from the pER 
lineage.  Arrow indicates budding and mature extracellular particles at 31,000-fold magnification.  
Micrograph courtesy of Dr. Fred Fuller. 
 
 
 
 
Fig.1.2. Electron micrograph of mature EIAV virus particles at a 38,000-fold magnification.  The virus 
was derived from the pER lineage, and was adapted to replicate in non-macrophage cell types as well as 
macrophages.  Micrograph courtesy of Dr. Fred Fuller. 
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Fig.1.3. Diagram showing the location of the three major genes gag, pol, and env in additional to the 
accessory genes tat, rev, and S2 on the EIAV genome. Courtesy of Dr. Susan Payne. 
 
 
 
1.2.1. Structural proteins 
1.2.1.1. Gag 
  Full length viral mRNA is used to synthesize Gag polyproteins in the cytoplasm 
(Vogt et al., 1975; Puffer et al., 1998).  The Gag polyproteins are then transported to the 
plasma membrane, where they assemble to form immature budding particles (Vogt et al., 
1975; Puffer et al., 1998).  The assembly of the Gag precursor proteins at the plasma 
membrane plays a crucial role in virus budding and release from the host cells (Leroux et 
al., 2004).  The binding of the Gag polyprotein to the host cell membrane induces the 
assembly and budding of retroviruses (Swanstrom and Willis, 1997).  Small regions of 
Gag, namely L (Late) domains also drive the final step of separation of the emerging 
viral particle (Swanstrom and Willis, 1997).  During or shortly after budding, cleavage 
of the EIAV Gag-precursor (Pr55gag) polyprotein by the viral protease generates the four 
major internal structural proteins of the mature virion: p15 matrix (MA), p26 capsid 
(CA), p11 and p9 nucleocapsid (NC) proteins (Hussain et al., 1988; Stephens et al., 
1986).  After the Gag polyprotein is cleaved into four different proteins, MA remains 
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associated with the inner face of the viral membrane, and CA forms a shell by 
condensing around the NC/RNA complex forming a mature infectious virion (Freed, 
1998).   
1.2.1.2. Pol 
Various enzymatic activities are performed by pol gene products produced by the 
cleavage of the EIAV Gag-Pol precursor (Pr180gag/pol) (Leroux et al., 2004). These 
activities include reverse transcriptase-RNaseH (p66), which is needed for the synthesis 
of DNA from viral RNA; a protease (p12) essential for the processing of the 
polyproteins Gag and Gag-pol during budding; a dUTPase (p15) necessary for EIAV 
replication in non- dividing monocytes-derived macrophages; and integrase needed for 
integration of the provirus (Threadgill et al., 1993; Lichtenstein et al., 1995; Steagall et 
al., 1995).   
1.2.1.3. Env 
The EIAV env gene is similar in organization to that of other retroviruses 
(Leroux et al., 2004).  The env gene encodes the SU (gp90) and TM (gp45) 
glycoproteins that become incorporated in the virus envelope (Leroux et al., 2004).  The 
glycoproteins SU and TM are virus specific surface “knobs” that are required for virus 
penetration of host cells and act as potent immuno-stimulants (Parekh et al., 1980).  SU 
contains over three times as many N-linked glycosylation sites (NX[S/T]) as TM, based 
on the deduced amino-acid consensus sequence of EIAVPV (Leroux et al., 1997).  This 
may explain the enhanced ability of SU to stimulate the production of antibodies 
(Leroux et al., 1997).  Based on binding assays from other lentiviruses, SU may interact 
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with equine lentivirus receptor-1 (ELR1), the newly identified cellular receptor for 
EIAV (Leroux et al., 2004; Ball et al., 2005; Zhang et al., 2005).   
During the course of infection and recurring disease, SU evolves rapidly 
(Hussain et al., 1987; Payne et al., 1989; Leroux et al., 1997).  Based on a study of 
antigenic variation within the env gene, SU can be divided into variable and conserved 
regions (Payne et al., 1987).  Based on amino acid sequence alignments of SU, variation 
is not random but is restricted to eight well-defined variable regions (V1 to V8) (Ball et 
al., 1992; Zheng et al., 1997a,b; Leroux et al., 1997).     
The role of mutations in the variable regions of SU was studied using 
monoclonal antibodies (Hussain et al., 1987).  Monoclonal antibodies that reacted with 
variable epitopes on SU effectively neutralized the virus, whereas the conserved epitopes 
of SU and TM reacted primarily with non-neutralizing antibodies (Hussain et al., 1987; 
Payne et al., 1989).  Studies using monoclonal antibodies identified three linear 
neutralizing epitopes on SU (Hussain et al., 1987; Ball et al., 1992).  Of the three 
neutralizing epitopes found, two consisted of amino acid residues within the V1 region 
(181-210).  V1 of EIAV is thought to correspond to the principal neutralizing domain 
(PND) or V3 in the surface unit of glycoprotein gp120 of HIV-1, as this region of EIAV 
SU has the potential to form a loop configuration stabilized by disulfide bonds (Ball et 
al., 1992; Cook et al., 1995). Thus, three separate EIAV SU domains (PND, 
hypervariable region and the region between) may be capable of inducing neutralizing 
antibodies (Zheng et al., 1997a).  
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Previous studies have suggested that the extracellular domain of TM is not likely 
to play a role in neutralization sensitivity (Cook et al., 1995).  The carboxy terminus of 
TM from SIV and HIV are shown to influence cytopathology, growth kinetics and viral 
infectivity (Chakrabarti et al., 1989; Lee et al., 1989; Chirmule et al., 1990; Rice et al., 
1990; Miller et al., 1991; Beisel et al., 1993).  The discovery of the Ttm, a protein 
encoded by the first exon of tat and a portion of the carboxy terminus of the TM protein-
coding region, could lead the discovery of a role in viral infectivity, growth kinetics, and 
cytopathology for the carboxy terminus of TM (Beisel et al., 1993). 
1.2.2. Non-structural proteins 
 Unlike the genomes for the primate lentiviruses HIV and SIV, which encode for 
six additional genes, the EIAV genome only has the capacity to encode three additional 
small accessory proteins originally designated S1, S2, and S3 (Leroux et al., 2004; Das 
and Jameel, 2005; Levy, 2006).  The EIAV S1 accessory protein is now commonly 
referred to as the EIAV transactivator protein (Tat) because it has a similar function to 
HIV Tat (Leroux et al., 2004).  The EIAV S2 accessory protein does not correspond in 
homology to other known lentiviral proteins (Leroux et al., 2004).  The EIAV S3 
accessory protein corresponds to HIV-1 Rev (Leroux et al., 2004).    
1.2.2.1. Tat 
The transactivator of transcription (tat) gene is located between the pol and env 
genes of EIAV (Dorn and Derse, 1988; Sherman et al., 1988).  Tat functions to 
transactivate the EIAV long terminal repeats (LTR) in order to activate viral gene 
expression (Dorn et al., 1990; Noiman et al., 1990).   EIAV gene expression is controlled 
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by the interaction between the EIAV Tat protein and the viral trans-activation responsive 
(TAR) element associated with the LTR (Leroux et al., 2004).  These functions make it 
likely that Tat is essential for the replication of EIAV (Fagerness et al., 2006; Desrosiers, 
2007).   
1.2.2.2. S2 
 EIAV S2 gene has a similar location to HIV vif between pol and env, but has no 
amino acid sequence homology to vif (Li et al., 1998), a lentiviral gene important for the 
replication of most lentiviruses in cultured cells (Desrosiers, 2007).  The S2 protein is 
comprised of only 65 amino-acids, but contains 3 highly conserved amino-acid motifs: a 
nucleoporin (GLFG) motif, a SH3 domain binding (PXXP) motif and a nuclear 
localization domain (RRKQETKK) motif (Li et al., 2000).  The detection of antibodies 
directed against S2 in naturally and experimentally infected animals confirms that S2 is 
produced in virus infected cells (Schiltz et al., 1992; Desrosiers, 2007).  One study 
suggests that S2 is a cytoplasmic protein that is not incorporated into viral particles 
(Yoon et al., 2000).  The role of S2 has been the focus of several studies, but its role in 
viral pathogenesis still remains unclear (Li et al., 2000; Fagerness et al., 2006).  S2 is not 
necessary for viral replication in vitro in a number of equine cell lines or in monocyte- 
derived macrophages as described in a few mutational studies involving the pathogenic 
molecular clone EIAV UK (Cook et al., 1998; Li et al., 1998).  Some of the same studies 
also found that S2 is not needed in the transition of latently EIAV-infected monocytes to 
differentiated productively infected macrophages (Li et al., 1998).  But more recent 
studies using a molecular clone containing a mutated S2 coding region have found S2 is 
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an important determinant of viral replication and pathogenesis during EIAV infection of 
horses and ponies (Fagerness et al., 2006; Li et al., 2000).  S2 deletion mutants 
replicated to lower levels (reduced viral RNA levels), did not induce clinical 
thrombocytopenia, and did not induce clinical signs when compared with the parental 
cloned EIAV (Li et al., 2000; Fagerness et al., 2006).   
1.2.2.3. Rev 
 All lentiviral genomes are relatively small and therefore must utilize complex 
molecular mechanisms to allow differential expression of viral proteins (Leroux et al., 
2004).  The use of suboptimal splice sites allows lentiviruses to utilize alternative RNA 
splicing that leads to the production of various mRNA from a primary transcript (Leroux 
et al., 2004).  During transcription the EIAV LTR regulates the production of full-length 
genomic and singly spliced mRNAs encoding the structural proteins Gag, Pol, and Env 
and small multi-spliced transcripts encoding the accessory proteins Tat, S2, and Rev 
(Rasty et al., 1990; Stephens et al., 1990).  The need for unspliced or partially spliced 
RNA has to be met by EIAV-infected cells, since most cellular mRNA is fully spliced 
before export into the cytoplasm (Leroux et al., 2004).  Rev (regulator of expression of 
viral proteins) is required for the expression of structural proteins and for virus 
production by allowing the translocation of unspliced and partially spliced mRNA from 
the nucleus to the cytoplasm (Martarano et al., 1994; Leroux et al., 2004; Fagerness et 
al., 2006).  EIAV Rev mediates the transport of spliced and unspliced viral transcripts 
from the nucleus to the cytoplasm by direct interaction with a 55-nucleotide region 
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located near the end of the env gene referred to as the Rev-responsive element (RRE) 
(Martanaro et al., 1994; Belshan et al., 1998; Chung and Derse, 2001).  
1.2.3. Long terminal repeats  
 EIAV transcriptional activity is regulated by the lentiviral LTR consisting of 
three segments U3 (unique, 3’ end), R (Repeated) and U5 (unique, 5’ end) (Leroux et al., 
2004).  The U3 region of the LTR contains elements that function as transcriptional 
enhancers (Payne et al., 1999). The U3 region is one of the most variable regions in the 
entire EIAV genome (Payne et al., 1999). This variation can be attributed to duplications 
in addition to deletions and nucleotide substitutions (Carpenter et al., 1991; Payne et al., 
1994; Maury et al., 1997).  LTR sequence variation can affect cell tropism, virulence, 
and replication (Payne et al., 1999; Payne et al., 2004; Hines et al., 2004; Maury et al., 
2005). A variety of cellular DNA-binding factors interact with specific motifs on the 
LTR sequence to control the EIAV promoter (Leroux et al., 2004). The compact EIAV 
promoter contains an enhancer made up of four basic DNA elements: a methylated 
DNA-binding protein site (MDBP), which can act either as a positive or a negative 
transcription factor; two PEA2 elements; a PEA3/ets motif; and, an AP-1 site (Carvalho 
and Derse, 1993a,b).  The ets binding motifs that interact with the macrophage- and B-
cell-specific transcription factor PU.1 (purine-rich element 1), required for viral 
transcription in primary macrophages, are also contained in the enhancer portion of the 
LTR (Carvalho and Derse, 1993(b); Lloberas et al., 1999; Hines et al., 2004).   
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1.3. EIAV replication 
Many nonprimate lentiviruses replicate primarily in macrophages because of the 
need for cellular transcription factors present in these cells (Gabuzda et al., 1989; 
Desrosiers, 2007).  EIAV is similar to maedi-visna virus (MVV) and caprine arthritis 
encephalitis virus (CAEV) in that viral replication occurs in macrophages (Narayan and 
Clements, 1989; Sellon et al., 1992; Montelaro et al., 1993; Narayan et al., 1993).  A 
number of studies have shown that mature tissue macrophages rather than peripheral 
blood monocytes are responsible for a majority of viral replication during EIAV 
infections (McGuire et al., 1971; Sellon et al., 1992; Oaks et al., 1998; Harrold et al., 
2000).  EIAV appears to target mature tissue macrophages of the spleen, liver, lymph 
nodes, kidney, lung, heart, brain, stomach, bone marrow, thymus, adrenals, and intestine 
(McGuire et al., 1971; Sellon et al., 1992; Desrosiers, 2007).  
The development of macrophages begins in the bone marrow as granulocyte-
macrophage progenitor cells which develop into monocytes (Ma et al., 2003; Narayan 
and Zink, 1988).  After leaving the bone marrow, monocytes circulate in the 
bloodstream for several hours before settling into their target tissue where they mature 
into tissue-specific macrophages such as the macrophage-like type A cells that line the 
synovium, Kuppfer cells of the liver, alveolar macrophages of the lung, or tissue 
macrophages in connective tissue (Ma et al., 2003; Narayan and Zink, 1988). 
Macrophages and monocytes are an important part of the innate immune system because 
they play a dual role in host defense (Ma et al., 2003).  Not only do macrophages play a 
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key role in innate immune response, but they also act as important accessory cells in the 
adaptive immune response (Ma et al., 2003).   
Although infection of monocytes with EIAV results in a nonproductive infection, 
they may serve as a reservoir and participate in the dissemination of the virus (Harrold et 
al., 2000).  Undifferentiated monocytes latently infected with EIAV are seen as “Trojan 
horses” because of their potential to disseminate the virus throughout the body without 
detection by the host immune system (Harrold et al., 2000).   
Renal macrovascular endothelial cells can also be infected with EIAV (Maury et 
al., 1998).  Macrovascular endothelial cells may also serve as a reservoir for virus 
infection, at least in long-term inapparent infections (Maury et al., 1998).  Another study 
also showed that endothelial cells are infected during acute, virulent infection (Oaks et 
al., 1999).  Vascular endothelial cells have been identified as a new in vivo host cell for 
EIAV, however, the role of endothelial cell infection in the pathogenesis or persistence 
of EIAV remains to be determined (Oaks et al., 1999; Harrold et al., 2000).  In vivo 
endothelial cell infection does not appear to be a determinant of virulence for EIAV, but 
endothelial cell infection could contribute to EIAV-associated thromobocytopenia (Oaks 
et al., 1999).  
  Some laboratory strains of EIAV, such as EIAVWSU5 and EIAVMA-1, have been 
adapted to replicate to high titer in vitro in equine macrophages (Kono et al., 1967), 
endothelial cells (Maury et al., 1998), equine dermis fibroblasts (ED) (Malmquist et al., 
1973; Klevjer-Anderson et al., 1979), fetal equine kidney (FEK) cells (Benton et al., 
1981), and canine and feline fibroblast cell lines (Klevjer-Anderson et al., 1979; Benton 
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et al., 1981).  Strains of EIAV previously grown in fibroblasts usually have a preference 
for replication in fibroblasts and are weakly virulent or avirulent in vivo, whereas strains 
obtained in vivo during a viremic episode or strains passaged in macrophages replicate to 
higher titers in primary equine macrophage cultures and are usually virulent when placed 
back into the horse (Carpenter and Chesebro, 1989; Perry et al., 1992).   
1.4. EIAV molecular clones 
In the beginning of EIAV research, cell-adapted laboratory strains derived from 
the Wyoming strain such as EIAVWSU5, EIAVPR (avirulent prototype), and EIAVPV (pony 
virulent) were used exclusively to study EIAV.  But these laboratory strains, like the 
primary isolate (EIAVWyo), contained a variety of genomic species.  In order to study the 
different aspects of EIAV replication, virulence and viral pathogenesis, molecular 
cloning was used to obtain a more homogenous genomic population.  The first full-
length EIAV molecular clone (CL22-V) was developed from the Malmquist strain of 
EIAV (Whetter et al., 1990).  This clone was a success in that it was able to replicate in 
both canine thymus (Cf2Th) cells and equine dermal cells, and horses infected with this 
clone developed an antibody response; however this clone did not cause clinical disease 
in horses and, therefore, was of little use in the study of virulence and viral pathogenesis 
(Whetter et al., 1990).  Two infectious molecular EIAV clones, pSPeiav19 and 
pSPeiav44, were developed from avirulent cell-adapted prototype (EIAVPR) Wyoming 
strain (Payne et al., 1994).  EIAV19, the virus stock derived from pSPeiav19, failed to 
cause disease in a Shetland pony infected model (Payne et al., 1994). Two more 
chimeric clones, p19/wenv16 and p19/wenv17, were generated when the 5’ and 3’ LTRs 
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and the env sequences of pSPeiav19 were replaced with those derived from the highly 
virulent Wyoming field strain EIAV (EIAVWyo) (Payne et al., 1998).  p19/wenv17 
plasmid was used to produce the virus stock EIAV17 that reproducibly causes acute 
disease in a Shetland pony model (Payne et al., 1998). 
Previous studies of in vivo virulence have focused on the LTR and env regions of 
EIAV (Payne et al., 2004).  Specifically the SU and TM regions of env are targeted in 
these studies (Payne et al., 2004).  In order to study the determining factors of EIAV 
virulence and pathogenesis two additional EIAV these clones, p17Nhe/19/wyoLTR and 
p19Nhe/17, were constructed to investigate the relative contribution of SU versus that of 
the TM/Rev region to the virulence phenotype of EIAV17 (Payne, et al., 2004).   The 
major difference in these clones is that p17Nhe/19/wyoLTR contains only the SU region 
from the virulent parent EIAV17, while p19Nhe/17 contains only the TM/Rev region 
from EIAV17 (Payne, et al., 2004).  The virus stock generated from p17Nhe/19/wyoLTR 
is designated EIAV17SU; the virus stock generated from p19Nhe/17 is designated 
EIAV17TM.  A commonality of these two clones is that they share common gag, pol, tat, 
and S2 sequences with both EIAV17 and EIAV19, but derive the LTRs from EIAV17 
(Payne, et al., 2004).     
1.5. EIAV transmission and pathogenesis  
EIAV is the only lentivirus for which there is reasonable proof of vector-borne 
transmission (Desrosiers, 2007).  Infection by EIAV occurs mainly by the transfer of 
blood between infected horses and uninfected horses by way of horseflies and deerflies 
that are interrupted during feeding (Hawkins et al., 1973; Hawkins et al., 1976; Kemen 
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et al., 1978; Issel and Foil, 1984). EIAV can also be spread through contaminated 
needles and instruments, blood transfusions and from mare to foal (Issel et al., 1985). 
The transmission of EIAV through breeding is rare (Kemen and Coggins, 1972; 
Tashjian, 1984).  Horses can become seropositive during any stage of disease, but may 
remain seronegative for as long as 45 days post-infection (Coggins et al., 1972; Issel and 
Coggins, 1979).  Like all lentiviruses, there is no effective vaccine or cure for EIAV, 
which results in a life-long infection (Leroux et al., 2004). 
Horses infected with EIAV, whether naturally or experimentally, may manifest 
one or more clinical stages of the disease (Russell et al., 1998).  At first exposure to 
EIAV, horses enter the acute stage of EIAV defined by a short period of disease that 
appears one week to one month post-infection and may be followed by chronic equine 
infectious anemia (EIA) (Issel and Coggins, 1979).  Both the acute and chronic stages of 
EIA may be characterized by clinical signs such as fever, anorexia, hemorrhages, 
lethargy, or thrombocytopenia, depending on the virulence of the EIAV strain 
(Montelaro et al., 1993).  Usually the acute stage is characterized by high fever, 
thrombocytopenia and occasionally anemia, while recrudescing fever, weight-loss, 
ventral edema, and severe anemia are seen in the chronic stage of EIA (Sellon, 1993). 
Hemolytic anemia may result as EIAV enters the bloodstream and antigen-antibody 
complexes form that associate with the surface of erythrocytes (Desrosiers, 2007).  The 
kidneys may also be affected by the formation of antigen-antibody complexes 
(Desrosiers, 2007).  The chronic phase of the disease, which can last up to a year or 
longer, is marked by recurring disease cycles (Leroux et al., 2004).  The frequency of 
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irregular cycles of viremia and the severity of the associated clinical signs usually 
decline over time as the horse enters the inapparent or subclinical stage of infection 
(Kono, 1973).  Rarely does acute or chronic EIA lead to death, unlike other lentiviruses, 
such as HIV, which result in a progressive degenerative disease and eventual death if left 
untreated (Issel and Coggins, 1979; Harrold et al., 2000).   
Greater than 90% of horses infected with EIAV undergo transition into the 
inapparent or subclinical state and appear clinically normal with no signs of disease 
(Olsen 2001; Montelaro et al., 1993).  In the inapparent or subclinical stage, overt 
clinical signs and viremia are absent for the normal life span of the horse (20 to 30 years) 
(Harrold et al., 2000; Montelaro et al., 1993).  However, inapparent carriers do show 
increases in plasma total solids and serum globulin concentrations and decreases in 
serum albumin concentration and serum albumin-to-globulin ratio, indicating a chronic, 
ongoing infection (Russell et al., 1998).  An inapparent or subclinical infection can be 
due to a number of factors such as contracting a less virulent strain of the virus or 
complex interactions between the horse’s immune system and the virus that eventually 
regulate virus replication (Sellon, 1993; Olsen, 2001).   
1.6. Equine cytokine production 
1.6.1. Equine immune activation and dysfunction during EIAV infection  
Cytokines induced by EIAV replication in the macrophage play an important role 
in the pathogenesis of EIA by affecting immune function and leading to the cell’s 
destruction (Narayan and Zink, 1988; Narayan and Clements, 1989; Montelaro et al., 
1993).  Lesions observed during necropsy of horses with acute and chronic EIAV, 
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include enlargement and accentuated lobular structure of the liver, enlargement of the 
spleen, ventral subcutaneous edema, generalized lymph-node enlargement, mucosal and 
visceral hemorrhages, and vessel thrombosis (Kono, 1973; Kemen and Coggins, 1972).  
An accumulation of lymphocytes and macrophages in periportal areas of the liver, and in 
lymph-nodes, adrenal gland, spleen, meninges, and lung can be observed 
microscopically (Henson and McGuire, 1971; Ishii and Ishitani, 1975; McGuire, 1986). 
It has been hypothesized that these lymphoproliferative lesions are the result of attempts 
by virus-reactive T-lymphocytes to control infection (Sellon et al., 1994).  Dysregulation 
or excessive production of cytokines by infected macrophages may result in the 
pathological propagation of subsets of lymphoid cells (such as cytotoxic T lymphocytes) 
and inhibition of others (such as helper T lymphocytes) causing these 
lymphoproliferative lesions (Narayan and Clements, 1989).   
 Following an acute episode of EIAV the hepatic lymphoproliferative lesions 
regress and become morphologically undetectable during the inapparent stage of EIA, 
but they will recur with the onset of clinical disease (Konno and Yamamoto, 1970; 
Henson and McGuire, 1971). Although the pathological and histological findings at 
necropsy are often unremarkable, inapparent carriers of EIAV may show signs of 
pathological changes in the kidneys and eyes (Konno and Yamamoto, 1970; Sellon et 
al., 1994).  Some pathological changes observed in inapparent carrier horses include an 
increase in cellularity and thickening of glomerular tufts of the kidney, retinal 
depigmentations and prominent choroidal vessels in the eyes, and chronic non-
 18
granulomatous choroiditis with foci of lymphocytic infiltrates in the eyes (Tashjian, 
1984; Sellon et al., 1994). 
Important insight into EIA pathogenesis in the horse can be provided by studying 
the equine immune system’s inflammatory response, such as measuring cytokine 
expression in EIAV-infected macrophages.  Investigating the dysregulation of cytokines 
secreted from EIAV-infected macrophages is important to the study of EIAV-induced 
pathogenesis for several reasons.  EIAV replication in vivo may be enhanced in several 
ways by the secretion of pro-inflammatory cytokines such as interleukins (IL-1α, IL-1β, 
IL-6, IL-8) and tumor necrosis factor alpha (TNF-α) by macrophages (Lim et al., 2005).  
Like HIV-1 and SIV, EIAV may recruit uninfected monocytes to the site of viral 
replication through pro-inflammatory cytokine simulation of monocyte chemotactic 
factors (Schmidmayerova et al., 1996; Zink et al., 2001).  Pro-inflammatory cytokines 
may also stimulate adhesion molecules that promote monocyte migration into tissue 
(Sampson et al., 2002) and induce EIAV-activating molecules by nonmonocytic cells 
(Lim et al., 2005).   
Cytokine dysregulation may coincide with clinical signs such as fever, anorexia, 
petechial hemorrhages, lethargy, anemia and thrombocytopenia (Montelaro et al., 1993; 
Lim et al., 2005).  Both IL-1 and TNF-α may contribute to EIA anemia by activating 
macrophages and neutrophils, thus enhancing phagocytosis of complement-coated 
erythrocytes and possibly downregulating erythropoietin production and dysregulating 
iron metabolism, thereby suppressing erythropoiesis (Sentsui and Kono, 1987a,b; 
Swardson et al., 1992; Sellon et al., 1994; Means, 1997, 2000).  Though multifaceted, 
 19
TNF-α effect on the bone marrow is largely suppressive (Tornquist et al., 1997).  
Megakaryocyte growth in vitro is also inhibited by TNF-α (Geissler et al., 1991). The 
injection of purified TNF-α in mice and humans suppresses the production of platelets 
and induces severe thrombocytopenia possibly by stimulating the secretion of platelet 
agonists (Michelmann et al., 1997; Tacchini-Cottier et al., 1998).  
TNF-α and IL-1 also have similar inflammatory effects which include the 
migration of leukocytes, activation of endothelial cells, and stimulation of the 
hypothalamic-pituitary axis (Tracey and Cerami, 1994).  IL-1, which induces the 
expression of prostaglandins, can have many local and systemic biological effects 
including fever, anorexia, and lethargy, all common signs of EIA (Dinarello, 1996).  IL-
1 can also induce the expression of other cytokines such as TNF-α and IL-6 (Gadient 
and Patterson, 1999). 
There is also a positive association between TNF-α activity in serum and plasma, 
as measured using the WEHI 164 clone 13 cytotoxicity assay, and viremia as indicated 
by fever, anemia and thrombocytopenia in EIAV-infected ponies (Costa et al., 1997).  
The same study also showed a positive correlation between TNF-α levels and both 
EIAV virulence and disease enhancement in ponies immunized with virus enriched 
major core protein-p26; these data suggest that TNF-α may also have a pathogenic role 
in acute disease (Costa et al., 1997).  Increases in serum TNF-α levels are seen during 
acute EIA infection in both immunocompetent and severe combined immunodeficiency 
(SCID) foals just prior to and at the onset of thrombocytopenia (Tornquist et al., 1997). 
These findings are not surprising in light of what is known about TNF-α effect on 
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immune response, which include signs of a host inflammatory response to microbial 
infection such as fever, anorexia and depression, all of which are clinical signs of EIA 
(Tornquist et al., 1997).  The biological effects of TNF-α are dose-dependent: prolonged 
exposure to low doses of TNF-α result in severe weight loss, anorexia, and muscle 
wasting, whereas high doses can result in shock, tissue injury, vascular leakage, hypoxia, 
and other pathological features indistinguishable from septic shock (Tracey and Cerami, 
1994).   
Earlier studies have also shown an increase in cytokine production during EIAV 
in vivo infection, specifically IL-6, TNF-α, transforming growth factor beta (TGF-β) and 
interferon alpha (INF-α) (Sellon et al., 1998; Tornquist et al., 1997). IL-1α, IL-1β, TNF-
α, and IL-6 induced by EIAV-infected macrophages are known for their pyrogenic 
activities (Dinarello, 1999).  In addition to fever, these cytokines lead to wasting 
diseases commonly seen in HIV/AIDS due to anorexia and hypermetabolism (Chang et 
al., 1998).  
A correlation between viremia and increased serum IL-6 levels in ponies infected 
with the virulent Wyoming strain of EIA also supports the link between viral replication, 
EIAV pathogenesis, and pro-inflammatory cytokines (Sellon et al., 1998). Viral 
stimulation of IL-6 production may contribute to the clinical disease seen in these ponies 
such as the development of fever (Helfgott et al., 1989), hypergammaglobulinemia and 
polyclonal B cell activation (McGuire et al., 1971; Russell et al., 1998). IL-6 also 
inhibits the production of IL-1 and TNF-α in vivo (Gadient and Patterson, 1999). 
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Chronic immune activation and dysfunctional cytokine production has been 
known to occur in other lentivirus-infected macrophages (Lechner et al., 1997; 
Legastelois et al., 1998; Fantuzzi et al., 2003). The secretion of proinflammatory 
cytokines IL-1, IL-6, IL-8, and TNF-α, as well as, IL-10 and INF-β have been linked to 
HIV infection of macrophages at all stages of HIV infection (Gessani et al., 1994; 
Fantuzzi, et al., 2000; Alfano and Poli, 2002). Although an increase in IL-8 expression 
has not been associated with EIAV infection, macrophages infected in vitro with CAEV 
have shown an increase in both IL-8 and monocyte chemoattractant protein 1 (MCP-1) 
expression while those infected with MVV have shown an increase in IL-8, IL-1 β, and 
TNFα (Lechner et al., 1997; Legastelois et al., 1998).  Enhanced IL-8 expression during 
CAEV infection in goats may also be responsible for the inflammation of the radiocarpal 
joints leading to arthritis, and the inflammation of other tissues such as the mammary 
gland, lungs, and brain (Lechner et al., 1997).  Further evidence of a correlation between 
cytokine dysregulation, lentivirus infection and pathogensis can be seen in MVV 
infection in sheep where an increase of IL-8, a CXC chemokine, may contribute to lung 
disease (Legastelois et al., 1998). The lung disease seen with experimental or natural 
infection MVV is characterized by interstitial pneumonia with mural and luminal 
alveolitis consisting mainly of macrophages, neutrophils, and lymphocytes (Cordier et 
al., 1990; Cordier et al., 1992), together with lymphocytic nodules and zones of smooth 
muscle hyperplasia (Mornex et al., 1994).  
In more recent EIAV studies, equine monocyte-derived macrophages (EMDM) 
infected with the virulent molecular clone EIAV17 showed increases in IL-1α, IL-1β, IL-
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6, IL-10 and TNF-α mRNA levels as early as 0.5 to 1 hour post-infection (hpi) (Lim et 
al., 2005).  These findings suggest that both in vitro and in vivo viral replication and thus 
EIAV pathogenesis may be modulated by pro-inflammatory cytokines (Lim et al., 2005).  
Lim et al. (2005) also reported different cytokine responses by virulent and avirulent 
EIAV clones, in particular the up regulation of mRNA expression of IL-1α, IL-1 β, 
TNF-α, IL-6, and IL-10 in vitro infection of EMDM with the virulent EIAV17 clone.  It is 
still unknown what factors influence cytokine induction and EIAV virulence.  Follow-up 
studies need to be done to determine whether, SU or TM, found in the env region, is the 
determining factor in cytokine induction and virulence. The four chimeric molecular 
clones EIAV17, EIAV19, EIAV17SU, and EIAV17TM mentioned earlier should be useful for 
these follow-up studies.  
1.7. Quantitative real-time polymerase chain reaction assay validation 
1.7.1. Introduction to quantitative real-time polymerase chain reaction  
The study of the equine immune system inflammatory response to EIAV has 
been restricted by the lack of reagents for measuring cytokine expression.  
Comprehensive immunoassay studies have been hindered by the fact, with the exception 
of TNF-α (Vick et al., 2007), that the expression of equine IL-1β, IL-6, and TGF-β can 
only be detected using antibodies specific to human or other animal cytokines 
(Billinghurst et al., 1995; Charan et al., 1997; Rodriguez et al., 1996).  The measurement 
of equine cytokine mRNAs is an alternative to immunoassays for the detection of 
cytokine expression (Cherwinski et al., 1987).  Various methods including reverse 
transcription competitive polymerase chain reaction (RT-cPCR), reverse transcription 
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polymerase chain reaction (RT-PCR), Southern blot techniques, quantitative real-time 
polymerase chain reaction (QPCR), and the ribonuclease protection assay (RPA) have 
been used to detect equine cytokine mRNA expression (Grünig and Antczak, 1995; 
Rottman et al., 1996; Byrne et al., 1997; Swiderski et al., 1999; Leutenegger et al., 1999; 
Giguère and Prescott 1999; Garton et al., 2002; Boyd, et al., 2003; Lim, et al., 2003; Lim 
et al., 2005; Murphy et al., 2007; Vick et al., 2007).   
QPCR is the most sensitive and accurate of the methods used to quantify the 
mRNA expression of cytokines, which are often expressed at very low levels (Wang and 
Brown, 1999; Blaschke et al., 2000).  QPCR (also known as real-time PCR, real-time 
quantitative PCR [RTQ-PCR]) became commercially available in 1997 (Isono, 1997; 
Wittwer et al., 1997).  QPCR, which is based on fluorescence-kinetic RT-PCR, allows 
the quantification of the PCR product in “real-time” by measuring PCR product 
accumulation during the exponential phase of the reaction (Blaschke et al., 2000; 
Giulietti et al., 2001).  Either a fluorescent dye (e.g., SYBR-Green or ethidium bromide, 
Higuchi et al., 1992) or labeled, sequence-specific probes (e.g., TaqMan®, Heid, et al., 
1996) can be used to monitor the simultaneous amplification and detection of specific 
DNA sequences (Giulietti et al., 2001).  QPCR offers many advantages over traditional 
RNA blot methods/techniques which include increased sensitivity and speed (Giulietti et 
al., 2001).  Not only is it much faster than previous RT-PCR methods, QPCR is less 
labor-intensive and lacks post-PCR processing of products, thus there is a high 
throughput with a reduced risk of contamination (Giulietti et al., 2001).  It also provides 
ultra-rapid cycling, which means it only takes 30 minutes to 2 hours to run an assay 
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(Blaschke, 2000).  QPCR also has a wide dynamic range of up to eight orders of 
magnitude and it requires 1000-fold less RNA than some conventional assays (Heid et 
al., 1996). It is also capable of detecting a 2-fold difference between samples; thus, it is 
specific, sensitive, reproducible, and not much more expensive than conventional PCR 
(http://www.dorak.info/genetics/realtime.html, 2007).   
1.7.2. Development of quantitative real-time polymerase chain reaction validation 
protocol 
  In order to perform additional studies on induction of cytokines by EIAV, a set 
of QPCR assays for the equine cytokines IL-1α, IL-1β, IL-6, IL-8 and TNF-α were 
validated using QPCR primers and probes which were generated for the equine IL-1α, 
IL-1β, IL-6, IL-8, TNF-α and 18S genes.  It was important to validate the QPCR assays 
for equine cytokines because previous publications describing primer/probe sets for 
equine cytokines did not include information regarding reproducibility (intra- and inter-
assay variability), efficiency, and specificity of the assays (Giguère and Prescott, 1999; 
Garton et al., 2002; Fumuso et al., 2003; Murphy et al., 2007; Vick et al., 2007).  Assays 
for the equine cytokines of interest are not commercially available in the TaqMan 
FAM/MGB probe format, and validated primers and probes are essential in studying the 
pathology of EIA as well as other equine diseases.   
 After the primer/probe pairs were designed using Applied Biosystem’s criteria, 
the efficiency and reproducibility of the assays were determined.  The primer/probe pairs 
were evaluated using five criteria: 1) the efficiency of the assays; 2) the inter-assay 
variation; 3) the intra-assay variation; 4) the amplification specificity of the assays; and, 
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5) the variation in RNA extraction and cDNA synthesis.  The efficiency of the 
primer/probe pairs should be between 90-100% (http://www.stratagene.com/ 
techtoolbox/calc/qpcr_slope_eff.aspx, 2007).  At a 100% efficiency the amplicon will 
double at each cycle (Gibson et al., 1996; Yuan et al., 2006).  
                               E = 10(-1/slope) –1                                                                     (1) 
The efficiency is derived from the slope of a standard curve in which the thres-
hold cycle is graphed against the log of the copy number (see equation 1). The slope of 
the line should fall between -3.1 to -3.6 (http://www.dorak.info/genetics/realtime.html, 
2007).  The threshold cycle (Ct) corresponds to the cycle number at which the 
fluorescence generated within a reaction crosses the threshold (http://www.dorak.info 
/genetics/realtime.html, 2007).  It is inversely correlated to the logarithm of the initial 
copy number (http://www.dorak.info/genetics/realtime.html, 2007).  Thus, the Ct value 
assigned to a particular sample reflects the point during the reaction at which a sufficient 
number of amplicons have accumulated (http://www.dorak.info/genetics/realtime.html, 
2007).   
The reproducibility of the assays was measured both by the inter-assay variation 
(the variation between runs performed on different days) and the intra-assay variation 
(the variation within an assay performed on the same day).  The coefficient of variation 
(CV), which is used to compare the variation across two sets of data, was used to 
measure the relative variability of the assays.  The coefficient of variation is derived 
from the ratio of the sample standard deviation to the sample mean multiplied by 100 
(see equation 2).  
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                                   CV   = σ  X 100%                                                              (2) 
                                              µ 
 The specificity of the assays was insured by performing gel electrophoresis and 
DNA sequencing on the products of the cytokine assays.  Bands corresponding to the 
target genes were seen and no non-specific amplification products were present.   
1.8. Hypothesis and objectives 
Fever, thrombocytopenia, hemorrhages, anorexia, and lethargy or seen in the 
acute and chronic phases of EIA may be due to the dysregulation or excessive 
production of cytokines by infected EIAV-infected macrophages.  Lim et al. (2005) 
reported different cytokine responses by virulent and avirulent EIAV.  In the current 
studies a set of recently described QPCR assays were used for the detection of equine 
cytokines IL-1α, IL-1β, IL-6, IL-8 and TNF-α to examine the effects of the EIAV Env 
proteins on cytokine expression by using chimeric viruses with different combinations of 
SU and TM.     
It was hypothesized that an increase in cytokine expression would be seen in 
equine macrophages infected with the virulent phenotype EIAV17 as compared to equine 
macrophages infected with the avirulent phenotype EIAV19.  Thus, there would be a 
positive correlation between virulence phenotype and an increased cytokine expression 
in equine macrophages.  It was also hypothesized that an increased cytokine expression 
would be seen in equine macrophages infected with EIAV17SU as compared to equine 
macrophages infected with EIAV17TM.   Thus, the SU region of the env gene would have 
a greater influence on EIAV virulence and cytokine induction than the TM region. 
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The specific objectives of this study were: 
1. To establish and validate cytokine assays using QPCR assays for the detection of 
equine cytokines IL-1α, IL-1β, IL-6, IL-8 and TNF-α; 
a.) Validate primers  and probes for equine IL-1α, IL-1β, IL-6, IL-8, and 
TNF-α; 
b.) Validate technique for isolating RNA and amplifying cDNA;  
2. To measure cytokine cDNA levels of IL-1α, IL-1β, IL-6, IL-8, and TNF-α in 
LPS-stimulated and unstimulated EMDM using QPCR; 
3. To measure cytokine cDNA levels of IL-1α, IL-1β, IL-6, IL-8, and TNF-α in 
EMDM infected with either virulent EIAV17 or avirulent EIAV19 using QPCR; 
and, 
4. To measure cytokine cDNA levels of IL-1α, IL-1β, IL-6, IL-8, and TNF-α in 
EMDM infected with EIAV17SU and EIAV17TM using QPCR. 
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CHAPTER II 
VALIDATION OF QUANTITATIVE POLYMERASE CHAIN REACTION ASSAYS 
FOR MEASURING CYTOKINE EXPRESSION IN EQUINE MACROPHAGES* 
2.1. Introduction 
The lack of reagents for measuring cytokine expression has limited the study of 
the equine immune system and the understanding of inflammatory responses and disease 
pathogenesis in the horse.  With the exception of TNF-α (Vick et al., 2007), specific 
monoclonal antibodies (mAb) and cytokine standards for the equine are very limited, 
and the expression of equine IL-1β, IL-6, and TGF-β can only be measured using 
antibodies specific to human or other animal cytokines.  This has impeded extensive 
studies using immunoassays (Billinghurst et al., 1995; Charan et al., 1997; Rodriguez et 
al., 1996).  An alternative to immunoassays for the detection of cytokine induction is the 
measurement of equine cytokine mRNAs (Cherwinski et al., 1987).  Methods that have 
been used to measure the expression of equine cytokine mRNAs include reverse 
transcription competitive polymerase chain reaction (RT-cPCR), reverse transcription 
polymerase chain reaction (RT-PCR), Southern blot techniques, quantitative real-time 
polymerase chain reaction (QPCR), and the ribonuclease protection assay (RPA) 
(Grünig and Antczak, 1995; Rottman et al., 1996; Byrne et al., 1997; Swiderski et al., 
1999; Leutenegger et al., 1999; Giguère and Prescott 1999; Garton et al., 2002; Boyd et 
____________ 
*Reprinted with permission from “Validation of quantitative polymerase chain reaction 
assays for measuring cytokine expression in equine macrophages” by Allen, C.A. et al., 
from J.Immunol. Methods doi: 10.1016/j.jim.2007.08.006 copyright © 2007 by Elsevier.  
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al., 2003; Lim, et al., 2003; Lim et al., 2005; Murphy et al., 2007; Vick et al., 2007).   
Previous studies that have explored the production of equine cytokines in 
macrophages using RT-cPCR and QPCR techniques (Giguère and Prescott, 1999; 
Garton et al., 2002; Fumuso et al., 2003; Murphy et al., 2007; Vick et al., 2007) lack 
information regarding reproducibility (intra- and inter-assay variability), efficiency and 
specificity of the assays.  While it is likely that the absence of validation data in some 
reports was due to limited manuscript lengths, it remains difficult to evaluate the utility 
of individual assays for diverse studies.  Therefore the main objective of our study was 
to develop and clearly evaluate a set of QPCR assays for the equine cytokines IL-1α, IL-
1-β, IL-6, IL-8, and TNF-α.  We describe primer and probe pairs for the listed cytokines 
that are sensitive, robust, and highly reproducible.  These assays were used to measure 
the effects of lipopolysaccharide (LPS) stimulation on equine monocyte-derived 
macrophages (EMDM) as a baseline for future studies.  
2.2. Methods 
2.2.1. Primer design 
Custom TaqMan® Gene Expression Assays of primer and probe sets for IL-1α, 
IL-1β, IL-6, IL-8, TNF-α, and 18S were designed using the Applied Biosystem’s 
Assays-by-DesignSM Service for Gene Expression Criteria.  Table 2.1 lists the sequences 
of the forward and reverse primers and the probe. The accession numbers for each gene 
are as follows: equine IL-6: U64794, AF041975, AF005227; equine IL-8: AY184956, 
CD53673, CD536703; equine IL-1α: CD466534, U92480; equine IL-1β: U92481, 
D42165, D42147; equine TNF-α: M64087, AB035735.  Available nucleotide sequences 
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for each cytokine were compared, and those with target regions that were fully 
conserved, free of base ambiguities, and were not within alternatively spliced regions 
were selected and submitted to ABI for primer and probe development.  All primer pairs 
were designed to produce amplicons smaller than 150 bp.  To prevent the amplification 
of genomic DNA, the primers were placed in consecutive exons with the probe spanning 
the junction between exons.  The 18S rRNA sequence M10098, AJ311673 was 
specifically chosen to be as universal as possible (Schmittgen and Zakrajsek, 2000; Aerts 
et al., 2004; Robinson et al., 2007) and to fit the parameters of the ABI 7500 Sequence 
Detection System (Applied Biosystems).  The 18S rRNA primers and probe were 
designed using the Applied Biosystem’s Assays-by-DesignSM Service, in order to be 
compatible with the TaqMan FAM/MGB probe format.  
2.2.2. TaqMan primer and probe validation 
Primer efficiency was determined using standard curves generated from 10-fold 
dilutions of plasmids encoding the transcript of each gene of interest.  Plasmids 
containing IL-1α, IL-1β, and IL-8 sequences were obtained from the Pratt Laboratory, 
Plant Biology Department, University of Georgia (http://www.fungen.org/Projects 
/Horse/Equus%20Project.htm). IL-6 and TNF-α cDNAs were generated by standard RT-
PCR and cloned using mRNA isolated from LPS-stimulated EMDM.  Plasmid DNA was 
isolated using the QIAprep Spin Miniprep Kit (Qiagen Inc. Valencia, CA), and plasmid 
concentration was determined by spectrophotometry. Dilutions were prepared in water 
such that the final copy number in the QPCR assay ranged from 10 to 105, and QPCR 
was preformed in triplicate.  QPCR using plasmid standards with the addition of cDNA 
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derived from unstimulated equine macrophages was also performed in order to evaluate 
primer efficiency in the presence of background cDNA. An additional measurement of 
efficiency of equine cytokine assays was performed by using 2-fold serial dilutions of 
cDNA generated from LPS-stimulated EMDM.  QPCR was performed in triplicate using 
the five cDNA dilutions to measure the efficiency of the five equine cytokine assays and 
the 18S housekeeping gene.  
 
Table 2.1                                                                                                            
Primers and probe combinations for quantitative real-time PCR                   
  
IL-6 f                5'-GAAAAAGACGGATGCTTCCAATCTG-3'             
IL-6 r                5'-TCCGAAAGACCAGTGGTGATTTT-3'                   
IL-6 p               5'-CAGGTCTCCTGATTGAAC-3'                                 
 
IL-8 f                5'-GCCACACTGCGAAAACTCA-3'                             
IL-8 r                5'-GCACAATAATCTGCACCCACTTTG-3'                
IL-8 p               5'-ACGAGCTTTACAATGATTTC-3'                           
 
IL-1α f              5'-CAATATCTTGCGACTGCTGCATTAA-3'           
IL-1α r              5'-CTCTTCTGATGTATAAGCACCCATGT-3'         
IL-1α p             5'-ACGCAGTGAAATTT-3' 
 
IL-1β f              5'-TGTACCTGTCTTGTGGGATGAAAG-3'              
IL-1β r              5'-GCTTTTCCATTTTCCTCTTTGGGTAA-3'            
IL-1β p             5'-CCTACAGCTGGAGACAGT-3'                              
 
TNF-α f            5'-TTCTCGAACCCCAAGTGACAAG-3'                 
TNF-α r            5'-GCTGCCCCTCGGCTT-3'                                     
TNF-α p           5'-ATGTTGTAGCAAACCC-3'   
 
18S f                 5'- AAACGGCTACCACATCCAA-3'                              
18S r                 5'-TCGGGAGTGGGTAATTTGC-3' 
18S p                5'-AAGGCAGCAGGCGC-3' 
_______________________________________________________________________ 
Sense primers are designated by (f), antisense primers by an (r), and the probe is designated by a (p). 
Probes are labeled with 5' 6FAM, fluorescent dye 6-carboxyfluorescein, and 3’MGBNFQ, a minor groove 
binder/non-fluorescent quencher. 
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Inter-assay variability was measured using three separate QPCR assays 
performed on three different days.  Intra-assay variability was measured by performing a 
single QPCR assay using 10 replicates of each of the following plasmid copy numbers 1 
x 105, 1x 103, 1 x 102, and 1 x101.  Analysis of the results included determination of the 
coefficient of variation (CV), the mean coefficient of variation, and the amplification 
efficiency. 
 The specificity of amplification was determined by performing gel 
electrophoresis and ethidium bromide staining on the QPCR products for each gene of 
interest to confirm product size and to detect the presence of any non-specific 
amplification products. The amplified DNA obtained from each primer pair was then 
purified using StrataPrep PCR Purification Kit (Stratagene, La Jolla, CA) and sequenced 
using BigDye® Terminator v1.1 (Applied Biosystems, Foster City, CA) on an ABI 
PRISM® 3100 Genetic Analyzer. 
2.2.3. Quantitative real-time polymerase chain reaction assay 
PCR reactions contained Custom TaqMan® Gene Expression Assays Mix 
(containing primers and probe), TaqMan® Universal PCR Master Mix (containing Taq, 
dNTPs and buffer), No AmpErase® UNG (final concentration 1X), and plasmid DNA in 
a volume of 20 μl. The samples were placed in 96-well plates and amplified in an 
automated fluorometer (ABI 7500 Sequence Detection System, Applied Biosystems). 
Amplification conditions were 2 min at 50°C, 10 min at 95.0°C, followed by 40 cycles 
of 15s at 95.0°C and 1 min at 60.0°C.  
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2.2.4. Isolation of peripheral blood mononuclear cells and establishment of equine 
monocyte-derived macrophage cell cultures 
EMDM cultures were established with methods adapted from Raabe et al. 
(1998).  Whole blood in the volume of 500ml was collected from EIAV-negative horses 
into an anticoagulant citrate dextrose (ACD) solution blood collection bottle (The Metrix 
Company, Dubuque, Iowa 52002, USA) and centrifuged at 700 x g for 20 min to 
produce buffy coats. EMDM were separated by density gradient centrifugation using 
HybriMax histopaque (d = 1.077g/cm3) cushion (Sigma, St. Louis, MO). The EMDM 
were washed four times with Dulbecco’s Ca2+ - and Mg2+ - free PBS (Sigma, St. Louis, 
MO), 5% adult horse serum (endotoxin and EIAV tested, Invitrogen/Gibco, Carlsbad, 
CA) and 1% penicillin-streptomycin solution (Sigma, St. Louis, MO). The EMDM were 
diluted in complete minimum essential medium alpha (MEM α) medium supplemented 
with 10% adult horse serum (Invitrogen, Carlsbad, CA) to a beginning concentration of 
5 x 106 cells/cm2, and 5 ml aliquots were added to 25 cm2 cell culture flasks and 
incubated at 37 °C in 5% CO2.  The next day (day 2), cells were washed to remove the 
non-adherent cells.  Cells were incubated for an additional 7 days to allow macrophages 
to mature. All reagents used for EMDM cultures were tested by the manufacturer for 
endotoxin and certified < 0.6 EU/mL endotoxin. In order to confirm the purity of the 
macrophage cultures, cell differentials were performed on cytospin preparations 
collected at days 1, 3 and 7 using 100μl samples. Cytospin preparations were stained 
with Wright’s-Giemsa and 100-cell differentials were performed.  Based on the 
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differentials the cell cultures were composed of 95% or greater macrophages at days 1, 3 
and 7. 
2.2.5. Stimulation of equine monocyte-derived macrophage cells with 
lipopolysaccharide 
LPS at 10ng/ml (Chen et al., 2003) or a negative control using complete MEM α 
medium was added to the cell cultures on day 7 of culture and incubated for 1 h at 37 °C 
in 5% CO2. Culture medium containing LPS or negative control was decanted, and cells 
were lysed by the addition of buffer RLT/ β-mercaptoethanol (Qiagen Inc., Valencia, 
CA).  Lysates were used for RNA preparation and cDNA synthesis to examine 
differences in cytokine expression between the stimulated and unstimulated cells.  
2.2.6. RNA isolation 
RNA was extracted from EMDM cultures using the Qiagen RNeasy® Mini Kit 
(Qiagen Inc., Valencia, CA) according to manufacturer instructions for isolation of total 
RNA from animal cells, with the exception that 1200 μl of buffer RLT/ β-
mercaptoethanol (Qiagen Inc., Valencia, CA)  was added to 25 cm2 cell culture flasks for 
cell lysis.  All RNA extractions were treated with 1 μl of DNase I Amp Grade 
(Invitrogen, Carlsbad, CA) for 15 min and then heated for 10 min at 65°C. RNA isolated 
from the EMDM cultures was used for cDNA synthesis.  
 
 
 
 35
2.2.7. cDNA synthesis  
  First-strand cDNA was synthesized from total RNA using SuperScript™ III First 
Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) according to manu-
facturer instructions in a 20 μl volume containing 200 U/μl SuperScript III RT, 1μg of 
total RNA, 50 ng/μl random hexamers, 10 mM dNTP mix, and DEPC-treated water. The 
reaction was carried out for 10 min at 25°C followed by 50 min at 50°C and was 
terminated at 85°C for 5 min. cDNA, synthesized from the total RNA, was amplified 
using the ABI 7500 Real-Time PCR System in order to determine cytokine expression 
using quantitative real-time PCR.  Relative quantification of the target was done using 
the signal from 18S M10098, AJ311673, a housekeeping gene, in each sample.  Raw 
data was analyzed using the 2-ΔΔCt method also known as the comparative threshold 
cycle (Ct) or ΔΔ Ct method (Livak and Schmittgen, 2001; Sabek et al., 2002), and the 
value for each sample was normalized using 18S as described in Applied Biosystems 
User Bulletin No. 2 (P/N 4303859) (http://docs.appliedbiosystems.com/pebiodocs 
/04303859.pdf,1997). 
2.3. Results 
2.3.1. Assay validation 
In order to determine the efficiency, repeatability, and reproducibility of the 
custom gene expression assays, five sets of plasmid DNA were analyzed using IL-1α, 
IL-1β, IL-6, IL-8, and TNF-α primers and probes. Amplification was linear over the 
range of 10 to 105 input copies of plasmid for all five of the equine genes.  A 
representive curve (IL-6) is shown in Fig. 2.1. The correlation coefficients of the 
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standard curves ranged from 0.9985-0.9993 (Table 2.2).  The standard curve efficiencies 
of the primers and probes ranged from 99% to 101% using a plasmid DNA template 
(Table 2.2).  The amplification efficiency of the target genes was approximately equal to 
that of 18S the housekeeping gene (Table 2.2).   
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Fig. 2.1.  Example of a standard curve for inter-assay validation for IL-6.  On the y-axis is the average 
threshold cycle value for IL-6 and on the x-axis is the log of the copy number for each IL-6 plasmid 
dilution.  
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Table 2.2 
Average correlation coefficients and amplification efficiencies of cytokine assays with plasmid DNA 
templates and cDNA dilutions 
_________________________________________________________________________________________________________ 
Cytokine                                   R2                                Efficiency______ 
IL-6                                   0.9985a         99.0%b 
IL-6 cDNA                     0.9918c                    91.0%d 
 
IL-8                              0.9990                  99.0%  
IL-8 cDNA                   0.9867                     86.0%  
 
IL-1 alpha                          0.9985                     99.7%           
IL-1 alpha cDNA              0.9840                     95.0 % 
 
IL-1 beta                             0.9993                    101.0% 
IL-1 beta cDNA                0.9819                     85.0% 
  
TNF-alpha                         0.9993                      99.2% 
TNF-alpha cDNA             0.9959                     83.0%   
 
18S cDNA                         0.9945                      90.0% 
Results presented as (a) and (b) are overall averages derived from data collected to determine intra-assay 
and inter-assay variability.   
Results presented as (c) and (d) are derived from dilutions of cDNA prepared from of LPS-stimulated 
EMDM.  
aAverage correlation coefficients of combined assays 
bAverage efficiency of combined assays 
c Correlation coefficient from one assay run in triplicate 
d Amplification efficiencies from one assay run in triplicate  
 
 
 
Repeatability and reproducibility of the QPCR assays were determined using 
intra-assay and inter-assay variation respectively.  Intra-assay variation was evaluated 
using 10 replicates containing plasmid copy numbers of approximately 105,103, 102,101.  
The mean CVs for each cytokine are presented in Table 2.3.  In no case was the intra-
assay CV for any cytokine, at any quantity of input plasmid, greater than 1.8%, 
demonstrating the repeatability of the reactions.   
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The inter-assay variation was determined by performing the assays 1-5 days apart 
on 3 different days using dilutions containing approximately 1x 105, 1 x 104, 1 x 103, 5 x 
102, 1 x102, 5 x101, and 1 x101 copies of plasmid.  For equine IL-6 the mean CV for each 
dilution factor across reactions ranged from 0.2% to 0.9% with an overall mean CV of 
0.5% (Table 2.3).  The mean CV for equine IL-8 ranged from 0.3% to 1.1% for each 
dilution factor across reactions and the overall mean CV for equine IL-8 was 0.6% 
(Table 2.3).  For equine IL-1α and IL-1β, the mean CV for each dilution factor across 
reactions ranged from 0.4% to 1.1%, and 0.2% to 1.0%, respectively.  The overall mean 
CV for IL-1 α and IL-1 β at all copy levels was 0.7 % and 0.5%, respectively (Table 
2.3).  The mean CV for equine TNF-α ranged from 0.6% to 1.1%, with a mean overall 
CV of 0.7% at all copy levels (Table 2.3).  In no case was the inter-assay CV for any 
cytokine, at any quantity of input plasmid greater than 1.1% demonstrating the 
reproducibility of the reactions.  The overall mean CV across all sets of intra- and inter-
assay data was 0.63% (range 0.2% to 1.8%) (Table 2.3).   In Table 2.3 we also show the 
ranges of Ct values for lowest (10 copies) and the highest (105 copies) amounts of 
template.  In no case was the Ct value for 10 copies of input plasmid greater than 35.82 
(Table 2.3).  The variability in Ct values did not increase at low template concentrations; 
the maximum range of Ct values was 2.06.   
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Table 2.3 
Reproducibility as measured with plasmid DNA templates 
____________________________________________________________________________________________ 
Cytokine                  Ct Rangec            Ct Ranged          Mean CV e 
IL-6 inter-assaya      (17.45-17.86)   (30.51-31.07)    0.5% 
IL-6 intra-assayb      (17.25-17.90)   (30.39-30.76)    0.6% 
 
IL-8 inter-assay       (20.84-21.55)   (33.54-34.55)  0.6% 
IL-8 intra-assay       (20.66-21.11)   (33.76-35.82)      0.8% 
 
IL-1α inter-assay     (18.48-18.90)   (31.73-32.93)      0.7% 
IL-1α intra-assay     (19.00-19.17)   (32.00-32.74)      0.6%  
 
IL-1β inter-assay     (19.87-20.29)   (32.36-33.51)     0.5% 
IL-1β intra-assay     (19.44-19.70)   (32.40-33.35)      0.6% 
 
TNF-α inter-assay   (17.47-17.79)      (30.39-31.43)  0.7% 
TNF-α intra-assay   (17.36-17.64)       (30.38-31.18)  0.7% 
_________________________________________________  
aInter-assay variability was measured using three separate QPCR assays 
 performed on three different days 
bIntra-assay variability was measured by performing a single QPCR assay 
c Range of cycle threshold for 10 copies of  plasmid DNA  
d Range of cycle threshold for 105copies of plasmid DNA 
e Mean of coefficient of variation 
 
 
 
To test the efficiency of the primer and probe sets under more stringent 
conditions, two other assays were performed. First, cDNA from unstimulated EMDM 
was added to plasmid dilutions to test the efficiency of the primers and probes in the 
presence of a non-specific competitor.  At input plasmid copy numbers of 5 x 102 to 105 
all reactions remained linear, with amplification efficiencies similar to reactions 
containing only plasmid.  However, at low levels of input plasmid (less than 100 copies) 
with the exception of IL-1α the curves were not linear, but started to plateau, as 
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indicated by the arrow in the example for IL-6 (Fig. 2.2).  The plateaus in the curves 
likely reflect the presence of cytokine mRNA in unstimulated EMDM.  In the presence 
of equine cDNA, the linear range for IL1-β and TNF-α was from 102 copies to 105 copies 
and the linear range for IL-6 and IL-8 was from 5 x 102 copies to 105 copies.  IL-1α 
remained linear to 10 copies of input plasmid (essentially identical to the curves without 
cDNA).   
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Fig.2.2. Example of a standard curve for IL-6 in the presence of background cDNA. The arrow indicates 
the start of a plateau.   
 
 
 
As the addition of cDNA from equine EMDM to plasmid DNA did not allow us 
to examine amplification efficiencies at levels below 100 copies of input plasmid, we 
performed dilutions of cDNA from LPS-stimulated EMDM.  In this instance we 
determined the efficiency of the equine cytokine gene expression assays and the 18S 
 41
housekeeping gene using a series of 2-fold dilutions (corresponding to 0.5 µl-0.03 µl of 
cDNA) from LPS-stimulated EMDM.  Amplification was linear for all five cytokines 
and the 18S housekeeping gene and a representative curve (IL-6) is shown in Fig. 2.3.  
At these lower levels of input template the assays remained linear (correlation 
coefficients of the standard curves ranged from 0.984-0.9959) but amplification 
efficiencies dropped (Table 2.2).   IL-1α performed the best with an efficiency of 95%; 
the least efficient primer and probe was TNF-α with an efficiency of 83% (Table 2.2).    
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Fig.2.3. Example of a standard curve for IL-6 in the presence of LPS-stimulated cDNA. 
 
 
 
2.3.2. Specificity of amplification of TaqMan assays 
It is typically understood that TaqMan assays are specific, however to insure we 
had the desired product; gel electrophoresis was used to analyze the products generated 
from each cytokine assay.  Bands corresponding to the expected sizes of the target genes 
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were seen, and no non-specific amplification products were present (data not shown).  
Each of the QPCR products was sequenced, and each product was found to be the 
sequence of interest (data not shown).   
2.3.3. Stimulation of equine monocyte-derived macrophage cells with 
lipopolysaccharide 
In order to provide useful comparisons for future studies three sets of  cDNA 
from EMDM stimulated with  LPS were analyzed by QPCR using IL-1α, IL-1β, IL-6, 
IL-8, and TNF-α primers and probes. Two EMDM cultures were from the same horse, 
collected one month apart, and the third set was from a different horse. RNA was 
isolated and cDNA was prepared as described in the materials and methods section. 
Cytokine expression levels varied between samples, but the general trend was the same 
for all three samples.  IL-1α showed the greatest induction levels while IL-6 showed the 
lowest induction levels (Fig. 2.4).  IL-1α levels were induced approximately 300- to 
30,000-fold.  IL-1β levels were induced 89-fold to 1554-fold.   TNF-α levels were 
induced from 30-fold to 280-fold.  IL-8 levels were induced from 53-fold to 133-fold.   
IL-6 levels were induced from 12-fold to 65-fold.   
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Fig.2.4. Induction of gene expression of equine cytokines after addition of 10ng/ml LPS to EMDM cells. 
Panel A horse Ely, Panel B & C horse 2000 1 month apart.  For each bleed date one cDNA reaction was 
prepared. Three separate QPCR were performed (each assay performed in triplicate). 
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Table 2.4 
Cycle threshold (Ct) values for LPS-stimulated and unstimulated EMDM 
___________________________________________________________________________________________________ 
Cytokinea                    Mean Ctb    Ct Rangec          S.D.d     Mean CV%e                 
IL-6 unstimulated       30.36       (27.13-34.25)       2.81            9.25 
IL-6 stimulated           25.89       (22.54-29.35)       2.66          10.27 
 
IL-8 unstimulated       27.67       (27.15-28.15)        0.32           1.16 
IL-8 stimulated           21.67       (19.67-23.79)        1.51           6.97 
 
IL-1α unstimulated     35.33       (32.58-37.65)        1.78           5.04 
IL-1α stimulated         24.85       (22.14-26.99)        2.01           8.09 
 
IL-1β unstimulated     31.41        (30.02-32.52)       0.98           3.12 
IL-1β stimulated         23.73        (20.39-26.77)       2.38         10.03 
 
TNF-α unstimulated   27.85        (26.67-28.82)       0.75           2.69 
TNF-α stimulated       20.81        (19.22-23.22)       1.40           6.73 
 
18S unstimulated         7.40           (6.30-8.46)         0.58           7.84 
18S stimulated             7.95           (6.93-9.66)         0.81         10.19 
_____________________________________________________________  
a Combined statistical analysis of cycle threshold values from three different samples (two samples were  
  from same horse taken one month apart) of unstimulated and LPS-stimulated EMDM measured using 
  three separate QPCR assays performed on three different days. 
b Mean constant threshold values for combined data from three different samples of EMDM from two 
  different horses.  
c Range for mean constant threshold values for combined data from three different samples of EMDM 
  from two different horses. 
d Standard deviation of constant threshold values for combined data from three different samples of  
  EMDM from two different horses. 
e Mean of coefficient of variation for combined data from three different  samples of EMDM from two  
  different horses. 
 
The constant threshold (Ct) values for the three sets of cDNA from unstimulated 
EMDM ranged from 26.67 for TNF-α to 37.65 for IL-α (Table 2.4).  The three sets of 
cDNA from LPS-stimulated EMDM had Ct values ranging from 19.22 for TNF-α to 
29.35 for IL-6 (Table 2.4). Values for the 18S housekeeping gene ranged from 6.30 to 
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8.46 for cDNA from unstimulated EMDM and from 6.93 to 9.66 for cDNA from LPS- 
stimulated EMDM (Table 2.4).  The average Ct value using cDNA from unstimulated 
EMDM for 18S was 7.40, the average Ct value using cDNA from LPS-stimulated 
EMDM for 18S was 7.95 (Table 2.4).   
2.4. Discussion 
QPCR is a rapid and reliable method for mRNA quantitation (Heid et al., 1996; 
Wang and Brown, 1999; Ficko and Černelč, 2005) however many QPCR primer and 
probe sets are poorly described and validation of many primer and probe sets is lacking.  
Although QPCR is a very specific and reproducible technique, in order for the results to 
be meaningful, validated primer and probe combinations must be available.  
In this study we have described a set of QPCR primers and probes for 
quantifying equine IL-6, IL-8, IL-1α, IL-1β, and TNF-α, and have demonstrated that 
these primer and probe sets were sensitive, specific, and reproducible.  Normalization to 
a relevant “housekeeping gene” is also important in the accuracy of QPCR.  The 18S 
ribosomal subunit was chosen because its cellular concentration is constant within a 
range of 1.0- to 4.2-fold (Schmittgen and Zakrajsek, 2000; Aerts et al., 2004; Robinson 
et al., 2007) which correlates to a difference of 0.5-2.0 Ct values, and its amplification 
efficiency of 90% (Table 2.2) is similar to that of the target genes.  Other housekeeping 
genes such as GAPDH and β-actin were considered, but were found to be inappropriate 
for our uses. GAPDH exhibited changes of up to 10-fold in expression in EMDM under 
varying conditions (J.Harrington, personal communication). Both GAPDH and β-actin 
are regulated within a 10-fold range and the transcription level can vary during cell 
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proliferation, differentiation, or activation (Schmittgen and Zakrajsek, 2000; Goidin et 
al., 2001; Frost and Nilsen, 2003; Aerts et al., 2004; Dheda et al., 2004).  18S and β-2 
microglobulin exhibit less variability and are therefore better internal controls (Goidin et 
al., 2001; Aerts et al., 2004). 
Primer and probe sets were initially evaluated using standard curves generated 
from 10-fold dilutions of double stranded circular plasmids encoding the transcript of 
each gene of interest.  The assays were linear over the range tested (10 to 105 copies of 
plasmid) and intra-and inter-assay variation was low.  Further, there was no correlation 
between template copy number and assay variation, suggesting that the assays are 
equally robust with low template amounts.  When we used more biologically complex 
samples (dilutions of cDNA) the primers and probes maintained acceptable, albeit lower 
efficiencies (Gallup and Ackermann, 2006).  Valid data can be obtained from efficienc-
ies less than 90%, if amplification is linear and the amplification efficiencies of the 
target and reference gene are approximately equal (http://docs.applied biosystems. 
com/pebiodocs/04303859.pdf, 1997; Livak and Schmittogen 2001; Gallup and Acker-
mann, 2006; http://www.dorak.info/genetics/realtime.html, 2007). 
Sensitivity of the assays was assessed using plasmid DNA dilutions.  All of the 
assays easily detected 10 copies of input plasmid.  To determine assay sensitivity for a 
more relevant (biologically complex) sample we added cDNA from unstimulated 
EMDM to plasmid dilutions.  However, the addition of cDNA from EMDM to plasmid 
did not serve to resolve sensitivity issues because at low levels of input plasmid the 
curves began to plateau.  It is likely that the point at which the plateau begins indicates 
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that the number of copies of plasmid and the number of copies of cDNA are 
approximately the same (between 100 and 500 copies for most of the cytokines tested).  
In the case of IL-6, when cDNA was added to the plasmid, the curve began to plateau at 
Ct values between 24 and 25 (Fig. 2.2); this corresponds reasonably well to the observed 
Ct values for IL-6 in unstimulated EMDM, which were as low as 27 (Table 2.4).  For IL-
1α (data not shown) the curves were the same with (R2 = 0.9925, amplification 
efficiency = 106%) and without (R2= 0.9985, amplification efficiency = 99.7%) cDNA.  
Ct values for IL-1α for unstimulated EMDM alone were between 32 and 37 (Table 2.4), 
similar to the Ct values obtained for 10 copies of plasmid (between 31 and 32) (Table 
2.3).  
We did not follow up further on the issue of absolute sensitivity as it was evident 
that all of the assays were capable of detecting cytokine expression in unstimulated 
EMDM.  In these experiments we generally recovered 5 µg of total RNA from 1.5- 2 x 
106 cells and 20 µl of cDNA  was prepared from 1 µg of RNA.  For all of the tested 
cytokine assays, amplification was positive using 0.5 µl of cDNA from unstimulated 
EMDM.  Dilutions of cDNA prepared from LPS-stimulated EMDM revealed that as 
little as 0.03 µl of cDNA was sufficient to generate a detectable signal.  Therefore, while 
we have not absolutely determined the sensitivity of these assays, they detect as little as 
10 copies of plasmid and are sufficiently sensitive to detect basal levels of cytokine 
expression in relevant cell types. Finally we examined product specificity by gel 
electrophoresis and DNA sequence analysis, to demonstrate that the assays were truly 
specific for the desired gene.   
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After extensive testing, the QPCR assays were used to determine the levels of 
cytokine induction in LPS-stimulated EMDM.  LPS was chosen for EMDM stimulation 
because it is a powerful activator of the innate immune system, and it is the best known 
and most thoroughly characterized inducer of inflammatory cytokines (Murtaugh et al., 
1996).  LPS induces the synthesis of a variety of cytokines and chemokines from 
mononuclear phagocytes; furthermore, LPS is potent inducer of both transcription and 
translation; a defined set of gene products, such as IL-1α, IL-1β, and IL-8 result from the 
stimulation of monocytes/macrophages with LPS (Chen et al., 2003).  LPS also induces 
the expression of TNF-α through a wide variety of agents that activate the nuclear 
transcription factor, NF-κ B (Myers and Murtaugh, 1995; Chen et al., 2003).   
Cytokines selected for this study, IL-6, IL-8, IL-1α, IL-1β, and TNF-α, are 
representative of the major inflammatory cytokines produced by macrophages 
(Murtaugh et al., 1996).  Few studies have been published that evaluate cytokine 
production in equine macrophages stimulated with LPS.  To the authors’ knowledge, 
only three studies have used QPCR to measure cytokine production in EMDM after LPS 
exposure.  Sykes et al. (2005) incubated equine peripheral blood mononuclear cells 
(PBMC) in the presence of LPS for 0 to 48 h and measured expression of TNF-α and IL-
1β mRNA.  Both  TNF-α and IL-1β showed a mean increase in mRNA expression of 
approximately 6-fold at 6 h; thereafter expression decreased slightly but remained 
significantly elevated at all time points compared with time 0 (Sykes et al., 2005).  
Laan et al. (2006) exposed recurrent airway obstruction (RAO) susceptible and 
nonsusceptible horses to aerosolized LPS, collected bronchoalveolar lavage fluid 
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(BALF), isolated equine alveolar macrophages at either 6 or 24 h post-exposure and 
measured levels of TNF-α, IL-1β, IL-8, and IL-6 mRNA.   A mean difference of 
approximately 7-fold was seen in TNF-α expression in RAO susceptible horses after 6 h, 
but had returned to baseline after 24 h (Laan et al., 2006).  A significant increase was 
seen in IL-1β and IL-8 expression; a mean difference of approximately 2-fold and 3-fold 
was seen for IL-1β and IL-8 respectively at 6 h (Laan et al., 2006).  A mean difference of 
approximately 4-fold was seen for IL-1β in RAO susceptible horses at 24 h (Laan et al., 
2006).   However, LPS-stimulation did not significantly alter the expression of TNF-α, 
IL-1β, IL-8, or IL-6 in RAO nonsusceptible horses at either 6 or 24 h (Laan et al., 2006). 
The third study measured IL-8 using QPCR of equine alveolar macrophages 
exposed to LPS for 48 h.  When compared to the untreated control, alveolar macro-
phages stimulated with LPS showed a mean increase of approximately 14-fold in IL-8 
expression (Jackson et al., 2004). 
It is not possible to make a direct comparison between this study of LPS-
stimulated EMDM and the aforementioned studies due to the differences in time points 
and study populations.  In the three cytokine studies mentioned above, TNF-α, IL-1β, 
and IL-8 had an induction range of 2-to14-fold over a period of 6 to 48 h.  However, the 
induction of cytokine gene expression upon LPS exposure of EMDM seen in this study 
was much greater than has been previously reported.  After 1 h of LPS exposure, we 
observed increases in IL-1α gene expression ranging from approximately 300- to 
30,000-fold.   IL-1β mRNA levels were induced 100- to 1500-fold.   TNF-α mRNA 
levels increased from 30- to 280-fold.  IL-8 mRNA levels increased from approximately 
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50- to 100-fold.   IL-6 mRNA levels increased from approximately 10- to 65-fold.  The 
time points used in the other assays (earliest measurement at 6 h) could be an important 
factor in the difference between previously reported cytokine levels and our results. 
Another likely explanation for the high levels of gene expression seen in this 
study is that the QPCR assays described herein are very sensitive and have a large linear 
range with baseline values easily detected in non-stimulated cells.  The inability to 
accurately measure basal levels of gene expression can reduce the ability to determine 
fold changes, as can the use of assays with limited dynamic range.  Another important 
aspect of this study was that great care was taken to use only endotoxin free media and 
PBS in our cell cultures, making the assay more sensitive to fold changes between the 
LPS-stimulated and unstimulated cells.  The data from this study was obtained using 
blood from two horses taken at three different time points which produced three 
independent cell cultures, each assayed in triplicate, and the general trend held true for 
both horses.  An increase of at least 10-fold was seen for IL-6, IL-8, IL-1α, IL-1β, and 
TNF-α in this study for both horses.   Although the absolute increases in cytokine gene 
expression were different for the two study animals, the relative trend in cytokine gene 
expression was the same.  IL-1α showed the greatest induction levels while IL-6 showed 
the lowest induction levels for the two study animals. 
In conclusion, we have validated a set of QPCR assays for the equine cytokines 
IL-1α, IL-1β, IL-6, IL-8 and TNF-α, and we have demonstrated these assays are 
sensitive, robust, and highly reproducible.  We propose that these assays are a valid way 
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to measure the effects of LPS stimulation on equine monocyte-derived macrophages and 
that our measurements can be used as a baseline for future studies.  
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CHAPTER III 
CYTOKINE DETECTION IN EIAV-INFECTED EQUINE MONOCYTE-DERIVED 
MACROPHAGES USING QUANTITATIVE REAL-TIME POLYMERASE CHAIN 
REACTION 
3.1. Introduction 
Equine infectious anemia virus (EIAV) belongs to the genus Lentivirus, which 
means “slow virus”, within the family Retroviridae (Desrosiers, 2007).  EIAV infects 
horses, donkeys and mules and results in a life-long infection for which there is no 
effective vaccine or cure (Leroux et al., 2004).  Based on both natural and experimental 
infections, equine infectious anemia (EIA) may present in one or more of the following 
clinical stages: acute, chronic, and inapparent (Hammond et al., 2000; Leroux et al., 
2004).  EIAV varies from other lentiviruses in that it causes a period of acute disease 
that appears 7 to 30 days post-infection that can be followed by chronic EIA (Olsen, 
2001).  During the acute stage of the disease, the horse may remain seronegative for as 
long as 45 days post-infection (Coggins et al., 1972; Issel and Coggins, 1979).  
The chronic phase of the disease, which can last for a year or longer, is 
characterized by irregular cycles of viremia and related clinical signs (Leroux et al., 
2004). Depending on the virulence of the EIAV strain, fever, anorexia, petechial 
hemorrhage, lethargy, or thrombocytopenia may be seen in the acute and chronic phases 
of the disease (Montelaro et al., 1993). High fever, thrombocytopenia and occasionally 
anemia are usually seen in the acute phase, while recrudescing fever, weight-loss, ventral 
edema, and severe anemia are seen in the chronic phase of the disease (Sellon, 1993).  
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During the chronic stage of the disease the frequency and severity of the clinical 
episodes, which can last 3 to 6 days, usually decline over time (Kono, 1973; Olsen, 
2001).  Infrequently, however the chronic stage may progress, resulting in chronic ill-
thrift and eventual death (Issel and Coggins, 1979; Harrold et al., 2000). 
About 90% of horses undergo transition to an inapparent or subclinical infection 
in which clinical signs appear to be absent for the normal life-span of the horse (20 to 30 
years), but the horse remains infected with EIAV (Harrold et al., 2000; Montelaro et al., 
1993).  These horses remain infective, possibly due to complex interactions between the 
horse’s immune system and the virus that eventually regulate viral replication (Olsen, 
2001). This is in contrast to other lentiviruses, such as human immunodeficiency virus 
(HIV), which result in a progressive degenerative disease and are fatal, when left 
untreated (Harrold et al., 2000). 
Viral replication of EIAV, as with most lentiviruses, occurs primarily in 
macrophages (Montelaro et al., 1993; Narayan and Clements, 1989; Narayan et al., 
1993; Sellon et al., 1992). In addition to their role as a reservoir of viral replication, 
macrophages also play an important role in the pathogenesis of EIA (Narayan and Zink, 
1988).  EIAV replication in the macrophage results in the cell’s destruction, but also 
induces the production of a variety of cytokines that may affect immune function 
(Narayan and Clements, 1989).  
Other lentiviruses are known to cause chronic immune activation and 
dysfunctional cytokine production in infected macrophages.  All stages of HIV infection 
are linked to the secretion of proinflammatory cytokines IL-1, IL-6, IL-8, and TNF-α, as 
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well as, IL-10 and INF-β from macrophages (Gessani et al., 1994; Fantuzzi, et al., 2000; 
Alfano and Poli, 2002).  Caprine arthritis encephalitis virus (CAEV)-infected 
macrophages show an increase in expression of IL-8 and monocyte chemoattractant 
protein 1 (MCP-1), while those infected with maedi-visna virus (MVV) show an 
increase in IL-8, IL-1 β, and TNFα (Lechner et al., 1997; Legastelois et al., 1998). Early 
studies of EIAV cytokine induction show an increase in IL-6, TNF-α, TGF-β and INF-α 
production in ponies and horses infected with EIAV (Sellon et al., 1998; Tornquist et al., 
1997). Studies performed in equine monocyte-derived macrophages (EMDM) infected 
with the virulent molecular clone p19/wenv17 (EIAV17) showed increases in IL-1α, IL-
1β, IL-6, IL-10 and TNF-α mRNA levels as early as 0.5 and 1 hour post-infection (hpi) 
(Lim et al., 2005). The production of these cytokines by infected macrophages may 
contribute to the cytopathic effect seen in the cells (Montelaro et al., 1993). 
Early laboratory strains of EIAV contained a variety of genomic species.  To 
study EIAV replication, virulence and viral pathogenesis, a more homogenous genomic 
population of viruses was needed.  The development of two infectious molecular clones, 
pSPeiav19 and p19/wenv17, has made it possible to study the effects of EIAV both in 
vivo and in vitro.  EIAV19 (Fig. 3.1) is an avirulent virus, derived from the infectious 
molecular clone pSPeiav19 (Payne et al., 1994; Payne et al., 2004). Shetland ponies 
infected with EIAV19, the virus derived from clone pSPeiav19, show no clinical signs of 
disease (Payne et al., 1994).  When the 5’ and 3’ long terminal repeats (LTR) and the 
env sequences of pSeiav19 are replaced with those derived from the highly virulent 
Wyoming field strain EIAV (EIAVWyo) a chimeric clone, p19/wenv17 is generated 
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(Payne et al., 1998). EIAV17, (Fig. 3.1) derived from molecular clone p19/wenv17, is a 
virulent virus that causes severe fever and thrombocytopenia at 5 to 8 days post-infection 
in Shetland ponies (Payne et al., 1998).  
 
 
Fig. 3.1. Diagram of the four EIAV clones EIAV19, EIAV17, EIAV 17SU, and EIAV17TM.  Courtesy of Dr. 
Susan Payne. 
 
 
Shetland ponies experimentally infected with EIAV17 develop fever and 
thrombocytopenia within 5 to 8 days post-infection (Payne et al., 1998), whereas ponies 
infected with 10-fold higher doses of EIAV19 remain free of clinical signs (Payne et al., 
1994). The differences in disease manifestation between EIAV19 and EIAV17 cannot be 
explained by differing levels of viral expression in cultured EMDM (Lim et al., 2005). In 
EMDM, both viruses replicate to high titer and induce cytopathic effects (CPE), 
indicating other factors are responsible for the difference in virulence (Lim et al., 2005).   
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A correlation between virulence phenotype and virally-induced increases of 
cytokine expression has recently been demonstrated in EMDM studies, using a 
ribonuclease protection assay (RPA) (Lim et al., 2005).  
To further explore the factors that influence cytokine induction and EIAV 
virulence a set of additional clones, p17Nhe/19/wyoLTR and p19Nhe/17, designated 
EIAV17SU and EIAV17TM, respectively, were developed (Fig. 3.1).  These clones were 
constructed to investigate the role of the env region in determining the virulence 
phenotype of EIAV17 (Payne, et al., 2004).  Because the env region contains both an 
surface (SU) and a transmembrane (TM)/Rev region, either one of these regions might 
play a greater role in virulence.  Thus two new molecular clones were constructed; the 
first, clone p17Nhe/19/wyoLTR, contains only the SU region from the virulent parent 
EIAV17; while the second, clone p19Nhe/17, contains only the TM/Rev region from 
EIAV17 (Payne, et al., 2004).  Both molecular clones have the same gag, pol, tat, and S2 
sequences as EIAV17 and EIAV19, but derive the LTRs from EIAV17 (Payne, et al., 
2004).    The clone p17Nhe/19/wyoLTR, also referred to as EIAV17SU, shares a portion of 
the SU region, from amino acids 147 to 444, with EIAV17 (Payne, et al., 2004).  Shetland 
ponies experience acute febrile episodes when infected with EIAV17SU (Payne, et al., 
2004).  It should be noted that although the infecting dose of EIAV17SU was up to 30-fold 
greater than that of the EIAV17, the resulting febrile episodes were less severe than those 
previously observed in ponies infected EIAV17 (Payne, et al., 2004).   
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The construct p19Nhe/17 also referred to as EIAV17TM contains the SU region 
from EIAV19 in addition to sharing some overlapping rev sequences and a portion of the 
TM region, amino acids 20 to 417 with  EIAV 17 (Payne, et al., 2004).  Although 2 
ponies received 6- to 20-fold more infectious EIAV17TM virus relative to the lethal dose 
of EIAV17, the  ponies infected with EIAV17TM never experienced a febrile episode; their 
body temperatures remained normal for more than 50 days post-infection (Payne, et al., 
2004).   Therefore the virulence phenotype of EIAV17 cannot be attributed solely to the 
TM/Rev region (Payne, et al., 2004).  The ponies in this study were infected with doses 
of either EIAV17SU or EIAV17TM, equivalent to or higher than the lethal dose of EIAV17, 
yet neither clone induced acute febrile episodes requiring euthanasia (Payne, et al., 
2004).   
We  studied the effects of EIAV17, EIAV19, EIAV17SU, and EIAV17TM on EMDM 
using a set of quantitative real-time polymerase chain reaction (QPCR) assays for the 
equine cytokines IL-1α, IL-1β, IL-6, IL-8, and TNF-α. We hypothesized that a positive 
correlation would be seen between the virulence phenotype of EIAV17 and an increased 
IL-1α, IL-1β, IL-6, IL-8, and TNF-α expression in EMDM. We also hypothesized that 
EMDM infected with EIAV19 (the avirulent clone) would show little or no increase in 
expression of equine cytokines.   We also predicted that there would be an increase in 
IL-1α, IL-1β, IL-6, IL-8, and TNF-α expression in EMDM exposed to EIAV17SU as 
compared to EMDM exposed to EIAV17TM.   It was thought that the greatest increases in 
expression of IL-1α, IL-1β, TNF-α and possibly IL-6 would be seen in EMDM exposed 
to EIAV17 or EIAV17SU.   
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3.2. Methods 
 
3.2.1. Isolation and establishment of equine monocyte-derived macrophage cultures 
Primary EMDM cultures were established as previously described (Allen et al., 
in press).  Briefly, whole blood was collected from EIAV-negative donor horses into an 
anticoagulant citrate dextrose (ACD) solution blood collection bottle (The Metrix 
Company, Dubuque, Iowa 52002, USA).  The blood was then centrifuged at 700 x g for 
20 min to produce buffy coats, and EMDM were separated by density gradient 
centrifugation using HybriMax histopaque (d = 1.077g/cm3) cushion (Sigma, St. Louis, 
MO). Dulbecco’s Ca2+ and Mg2+ - free PBS (Sigma, St. Louis, MO), 5% adult horse 
serum (endotoxin and EIA tested, Invitrogen/Gibco, Carlsbad, CA) and 1% penicillin-
streptomycin solution (Sigma, St. Louis, MO) were used to wash the EMDM four times. 
Complete minimum essential medium alpha (MEMα) medium supplemented with 10% 
adult horse serum (Invitrogen, Carlsbad, CA) was used to dilute the EMDM to a initial 
concentration of 5 x 106 cells/cm2.  One-ml aliquots of the EMDM/MEMα suspension 
were added to each of the 12-wells of a Poly-D-Lysine plate (Becton Dickinson 
Labware) and incubated at 37 °C in 5% CO2.  Non-adherent cells were removed the 
following day (day 2) by washing with Dulbecco’s PBS and the resulting culture of 
adherent cells was incubated for an additional 7 days. All reagents were manufacturer 
tested and certified < 0.6 EU/mL endotoxin for use in EMDM cultures.  It was estimated 
that the macrophage cultures had a 95% or greater purity based on 100-cell differentials 
performed on cytospin preparations stained with Wright’s-Giemsa and collected at days 
1, 3 and 7 using 100μl samples.   
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3.2.2. Virus stocks 
 Molecular clones EIAV17, EIAV19, EIAV17SU, and EIAV17TM were prepared as 
previously described (Payne, et al., 1998; Payne et al., 2004).  Viral stocks were 
amplified by infecting EMDM with approximately 4,000 counts per minute (cpm) of 
reverse transcriptase (RT) activity in 1.0 ml.  Culture supernatants from infected EMDM 
were collected 5 to 15 days post-infection. An increase in RT activity was used to 
measure the virus growth. The infected culture supernatants were ultrafiltered against 
500 ml fresh complete MEMα, without horse serum, using a Vivaflow 200 tangential-
flow ultrafiltration unit (Sartorius Corp. Edgewood, NY) with a MWCO of 100 kDa in 
order to remove any cell-secreted molecules (especially cytokines molecular weights of 
cytokines range from 7 to 75 kDa) (Lim et al., 2005).  The RT activity of the 
concentrated viral supernatants was remeasured after ultrafiltration. Culture supernatant 
of mock-infected EMDM was collected and purified under identical conditions, and was 
used as control medium (CM). Purified CM, EIAV17, EIAV19, EIAV17SU, and EIAV17TM 
contained negligible levels of endotoxin (below 0.25 EU/ml). 
3.2.3. Infection of equine monocyte-derived macrophages 
Cytokine profiles of infected EMDM were determined after exposure to a 
virulent strain of EIAV (EIAV17), an avirulent strain of EIAV (EIAV19), EIAV17SU, and 
EIAV17TM clones.  Mock-infected EMDM was used as a negative control. At 7 days 
post-isolation of macrophages, EIAV19, EIAV17, EIAV17SU, and EIAV17TM (containing 
30,000 cpm of RT activity in 1 ml) or 1 ml of complete MEM α medium was added to 
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each 12-well plate, and incubated for 1 h at 37 °C in 5% CO2.  Culture medium 
containing EIAV19, EIAV17, EIAV17SU, EIAV17TM, or negative control was decanted 
from the cells which were lysed by the addition of buffer RLT/ β-mercaptoethanol 
(Qiagen Inc., Valencia, CA).  Lysates were used for RNA preparation and cDNA 
synthesis as described previously in Allen et al., (in press).  At 1 hpi cells were washed 
with PBS and lysed by the addition of buffer RLT/ β-mercaptoethanol (Qiagen Inc., 
Valencia, CA). Cell lysates were stored at -80°C.  The experiments were repeated in 
triplicate using blood collected from three different horse donors.  
3.2.4. RNA isolation 
As previously described in Allen et al., (in press), total RNA was isolated from 
EMDM cultures using the Qiagen RNeasy® Mini Kit (Qiagen Inc., Valencia, CA). 
Briefly, the manufacturer instructions were followed for the total isolation of RNA from 
animal cells.  In order to eliminate any DNA contamination, the extracted RNA was 
treated with the addition of 1 μl of DNase I Amp Grade (Invitrogen, Carlsbad, CA) for 
15 min before being heated for 10 min at 65°C. After most of the DNA was removed, 
the isolated RNA was used for cDNA synthesis.  
3.2.5. cDNA synthesis  
SuperScript™ III First-Strand Synthesis System for RT-PCR (Invitrogen, 
Carlsbad, CA) was used to synthesize first-strand cDNA from total RNA, as previously 
described in Allen et al., (in press). Briefly, 200 U/μl SuperScript III RT, 50 ng/μl 
random hexamers, 10 mM dNTP mix, and DEPC-treated water were added to 1 μg of 
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total RNA for a total volume of 20 μl.  The reaction conditions used were as follows: 
25°C for 10 min, followed by 50°C for 50 min, and then the reaction was terminated 
after 5 min at 85°C.  The ABI 7500 Real-time PCR System was used amplify the 
resulting cDNA and determine the cytokine expression using QPCR. 
3.2.6. Primer design 
Primer and probe sets were designed and validated as previously described in 
Allen et al., (in press). Applied Biosystem’s Assays-by-DesignSM Service for Gene 
Expression Criteria was used to design Custom TaqMan® Gene Expression Assays for 
IL-1α, IL-1β, IL-6, IL-8, TNF-α, and 18S. The following is a list of accession numbers 
for each gene: equine IL-1α: CD466534, U92480; equine IL-1β: U92481, D42165, 
D42147; equine IL-8: AY184956, CD53673, CD536703; equine TNF-α: M64087, 
AB035735; equine IL-6: U64794, AF041975, AF005227; and, the 18S housekeeping 
gene M10098, AJ311673.  Briefly, the primers were placed in consecutive exons with 
the probe spanning the junction between exons to prevent the amplification of genomic 
DNA.  In addition all primer pairs were designed to produce amplicons smaller than 150 
bp.  After a comparison of available nucleotide sequences, those target regions that were 
fully conserved, free of any base ambiguities, and not within alternatively spliced 
regions were submitted to ABI for primer and probe development.   
3.2.7. Quantitative real-time polymerase chain reaction assay 
As previously described in Allen et al., (in press), the final PCR reactions 
contained TaqMan® Universal PCR Master Mix (containing Taq, dNTPs and buffer), 
No AmpErase® UNG (final concentration 1X), Custom TaqMan® Gene Expression 
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Assays Mix (containing primers and probe), and cDNA sample in a total volume of 20 
μl.  The PCR reactions were amplified in an automated fluorometer (ABI 7500 Sequence 
Detection System, Applied Biosystems), using the 96-well plate format.  Amplification 
conditions for the reactions were 2 min at 50°C, 10 min at 95.0°C, followed by 40 cycles 
at 95.0°C for 15s and then a terminating step of 1 min at 60.0°C.   
3.2.8. Data analysis 
Relative quantification of the target in each sample was performed using the 
signal from 18S M10098, AJ311673, a housekeeping gene. Raw data were analyzed 
using the ∆∆CT method, also known as the comparative threshold cycle (Ct) (Livak and 
Schmittgen, 2001; Sabek et al., 2002), and the value for each sample was normalized 
using 18S M10098, AJ311673 (Applied Biosystems User Bulletin No. 2 (P/N 4303859); 
http://docs.appliedbiosystems.com/pebiodocs/04303859.pdf, 1997).  Negative RT samp-
les as well as samples without cDNA template were included in reactions to check for 
contamination.  The results were presented as fold-increase in cytokine expression of 
cells infected with either EIAV17, EIAV19, EIAV17SU, or EIAV17TM over those of CM-
treated cells. 
3.3. Results 
3.3.1. Expression of IL-α, IL-1β, IL-8, IL-6 and TNF-α in equine monocyte-derived 
macrophages infected with EIAV clones 
 EMDM derived from the peripheral blood of three different horse donors was 
exposed for 1 h to EIAV17, EIAV19, EIAV17SU, EIAV17TM, and CM.  RNA was isolated 
and cDNA was prepared as described in the materials and methods section. Three sets of 
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cDNA from EMDM exposed to the four EIAV clones and CM were analyzed by QPCR 
using IL-1α, IL-1β, IL-6, IL-8, and TNF-α primers and probes. Fig. 3.2 shows the 
results, presented as a ratio of fold-increase of EIAV-treated cells over CM-treated cells, 
for three different horses.  
 Horse A showed increases in IL-1α, IL-1β, and TNF-α in cells exposed to 
EIAV17, EIAV17SU, and EIAV17TM relative to CM, while IL-1α, IL-1β, IL-6, IL-8 and 
TNF-α were down-regulated in cells exposed to EIAV19 (Fig. 3.2).  There was not a 
consistent pattern of induction among EIAV17, EIAV17SU, and EIAV17TM; increases in 
expression varied among cytokines (Fig. 3.2). 
 For horse B IL-1α, IL-1β, and TNF-α were up regulated in cells exposed to 
EIAV17, EIAV17SU, and EIAV17TM relative to CM (Fig. 3.3).  Cells exposed to EIAV19 
demonstrated a down-regulation of IL-1β, IL-6, and IL-8 expression (Fig. 3.3).  
 For unknown reasons, horse C exhibited a different pattern of induction from the 
other two horses.  Cells exposed to either EIAV17, EIAV17TM, or EIAV19 showed an 
increase in TNF-α expression, but also showed a decrease in IL-1α, IL-1β, and IL-6 
expression (Fig. 3.4).  Unlike the other two horses, there was no difference in cytokine 
induction between cells exposed to the virulent clone EIAV17 and those exposed to 
EIAV19 the avirulent clone (Fig. 3.4).    
 When the data from all three horses were averaged, a general trend emerged. 
Although cytokine expression levels varied between horses, the EMDM exposed to 
EIAV17, EIAV17SU, and EIAV17TM showed the greatest induction levels in IL-1α, IL-1β, 
and TNF-α expression, but showed a down regulation of IL-6 expression (Table 3.1).  
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Looking at EMDM from individual horses, IL-1α reached a peak induction of 7.2-fold 
relative to CM (Fig. 3.3).  IL-1β peaked at 7.86-fold over CM (Fig. 3.3).  The highest 
induction of TNF-α was 4.44-fold over CM (Fig. 3.3).  Insignificant induction rates were 
seen for IL-8 and IL-6, with 1.76-fold and 1.22-fold increases over CM respectively 
(Fig. 3.2 and Fig. 3.3).  Unlike IL-1α, IL-1β, and TNF-α, it appears that IL-6 and IL-8 
cDNA expression was unregulated by CM treatment.  
Increases in IL-1α (2.5-fold), IL-1β (2.1-fold), and TNF-α (3.2-fold), relative to 
CM treated EMDM, were detected in EMDM treated with EIAV17, (Table 3.1).  EIAV17- 
treated EMDM consistently expressed higher levels of IL-1α and IL-1β than EIAV19- 
treated EMDM (Fig. 3.2, Fig. 3.3, and Fig. 3.4).  Increases in expression were not seen 
for IL-6 or IL-8 in EIAV17- treated EMDM (Fig. 3.2, Fig.3.3, and Fig. 3.4).   
Increases in IL-1α (3.6-fold), IL-1β (3.5-fold), and TNF-α (3.1-fold) were seen 
in EMDM treated with EIAVSU, relative to CM-treated EMDM (Table 3.1).  EIAV17SU- 
treated EMDM consistently expressed higher levels of IL-1β and TNF-α than EIAV17TM- 
treated EMDM (Fig. 3.2, Fig. 3.3, and Fig. 3.4).  EIAV17SU-treated EMDM consistently 
expressed higher levels of IL-1α and IL-1β than EIAV19-treated EMDM (Fig. 3.2, Fig. 
3.3, and Fig. 3.4). 
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  Fig. 3.2. Induction of gene expression of equine cytokines for horse A EMDM treated with either 
  EIAV17, EIAV17SU, EIAV17TM, EIAV19  relative to CM-treated cells. Each assay was performed in 
  triplicate. 
 
 
 
            Horse B Cytokine Expression
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  Fig.3.3. Gene expression of equine cytokines for horse B EMDM. Each assay was performed in triplicate. 
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  Fig. 3.4. Gene expression of equine cytokines for horse C EMDM. Each assay was performed in triplicate. 
 
 
 
 
 
Table 3.1 
Comparison of cytokine expression in EIAV17, EIAV19, EIAVSU, and EIAVTM- infected EMDM to CM-treated 
EMDM at 1 hpi 
Cytokine   EIAV17            EIAV19                 EIAV17SU          EIAV17TM 
                  Ratioa           Ratioa             Ratioa             Ratioa 
IL-1α         2.53              0.92                 3.60              3.07 
 
IL-1β         2.08              0.48                 3.46              1.88 
 
IL-6           0.63              0.26                 0.32              0.39 
 
IL-8           0.92              0.63                 1.17              0.93 
 
TNF-α       3.21               1.74                 3.08             2.41 
These results are overall averages derived from data collected from three horses. 
aAverage ratio of EIAV-infected EMDM over control media. 
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3.4. Discussion 
In the present study we utilized a set of QPCR primers and probes for 
quantifying equine IL-6, IL-8, IL-1α, IL-1β, and TNF-α in order to investigate the 
dysregulation of cytokines secreted from EIAV-infected macrophages.  The 
investigation of cytokines secreted from EIAV-infected macrophages is essential to the 
understanding of EIAV-induced pathogenesis for a number of reasons. Pro-
inflammatory cytokines such as IL-6, IL-8, IL-1α, IL-1β, and TNF-α may enhance EIA 
pathogenesis by supporting viral replication in vivo (Lim et al., 2005).  There is also 
evidence that lentiviruses such HIV-1, simian immunodeficiency virus (SIV), and 
possibly EIAV may use monocyte chemotactic factors stimulated by the release of pro-
inflammatory cytokines from infected macrophages to recruit uninfected monocytes to 
the site of viral replication (Schmidmayerova et al., 1996; Zink et al., 2001).  Other ways 
pro-inflammatory cytokines may enhance EIAV replication include the induction of 
EIAV-activating molecules by nonmonocytic cells (Lim et al., 2005) and the stimulation 
of adhesion molecules that promote monocyte migration into tissue (Sampson et al., 
2002).  
The cytokines IL-1α, IL-1β, IL-6, IL-8, and TNF-α were chosen for this study, 
based on previous EIA research.  Clinical signs of EIA such as fever, anorexia, petechial 
hemorrhages, lethargy, anemia and thrombocytopenia are thought to coincide with the 
secretion of these cytokines (Montelaro et al., 1993; Lim et al., 2005).  Both IL-1 and 
TNF-α may contribute to EIA-induced anemia by suppressing erythropoiesis while 
enhancing phagocytosis of complement-coated erythrocytes (Sentsui and Kono, 1987a, 
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1987b; Swardson et al., 1992; Sellon et al., 1994; Means, 1997, 2000).  EIA anemia may 
be further intensified by the inflammatory effects of IL-1 and TNF-α which include the 
stimulation of the hypothalamic-pituitary axis and the activation of endothelial cells and 
leukocytes (Tracey and Cerami, 1994).    
Other indicators of viremia such as fever, anemia and thrombocytopenia have 
been linked to increased levels TNF-α activity in sera and plasma in EIAV-infected 
ponies (Costa et al., 1997).  There is also evidence of a positive relationship between 
TNF-α activity in both sera and plasma and EIAV virulence and disease which suggest 
TNF-α may also have a pathogenic role in acute disease (Costa et al., 1997).  
   Another important link between viral replication, EIAV pathogenesis, and pro-
inflammatory cytokines is the correlation between viremia and increased serum IL-6 
levels in ponies infected with virulent EIAV (Sellon et al., 1998).  The secretion of IL-6 
by EIAV-infected macrophages may contribute to the clinical disease seen in these 
ponies, such as the development of fever (Helfgott et al., 1989), 
hypergammaglobulinemia, and polyclonal B cell activation (McGuire et al., 1971; 
Russell et al., 1998). Other studies show an increase in IL-6, TNF-α, TGF-β and INF-α 
production during EIAV infection in vivo (Sellon et al., 1998; Tornquist et al., 1997).  
Although a majority of the data collected on cytokine dysregulation during EIAV 
infection points to the secretion of TNF-α and IL-6 by macrophages, IL-1 can have 
many local and systemic biological effects including fever, anorexia, and lethargy that 
are correlated with the clinical signs of EIA (Dinarello, 1996).  While increases in IL-8 
and MCP-1 expression have not been associated with EIAV infection, macrophages 
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infected with CAEV and MVV show increases in IL-8, IL-1 β, MCP-1 and TNFα 
(Lechner et al., 1997; Legastelois et al., 1998).   
Increases in IL-1α, IL-1β, IL-6, IL-10 and TNF-α mRNA expression show up as 
early as 0.5 hpi  in EMDM infected with the virulent molecular clone EIAV17 (Lim et 
al., 2005).  The secretion of pro-inflammatory cytokines such as IL-1α, IL-1β, IL-6, IL-8 
and TNF-α by infected macrophages may enhance EIAV replication in vivo and thus 
EIA pathogenesis (Lim et al., 2005). 
Many questions still need to be answered about the role of EIAV virulence in 
producing pro-inflammatory cytokines by infected macrophages and the influence of 
these cytokines on EIAV replication and pathogenesis.  In order to discover the factors 
that determine virulence, and thus EIA pathogenesis, cytokine induction was studied 
using four chimeric molecular clones, EIAV17, EIAV19, EIAV17SU, and EIAV17TM.  
 Four well-defined and biologically distinctive EIAV molecular clones were used 
to infect EMDM, the natural host cells for EIAV. The development of these infectious 
molecular clones has made it possible to study the effects of EIAV both in vivo and in 
vitro.  The gag, pol, tat and S2 sequences of EIAV17 and EIAV19 are identical, but these 
viruses differ in their long terminal repeats (LTR)s, env and rev sequences, with the 
regions of greatest sequence divergence occurring in SU and the U3 enhancer (Payne et 
al., 2004). Using chimeric clones, studies designed to define the major virulence 
determinants of EIAV17 show that both the env and LTR sequences of EIAV17 are 
required for the acute virulence phenotype (Payne et al., 2004).  Replacement of either 
the env or LTRs sequences of EIAV17 with those of EIAV19 abolishes EIAV17 virulent 
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effects (Payne et al., 2004). There is a difference of 30 amino acids in the SU region and 
17 amino acids in the TM region of EIAV17 and EIAV19, giving them biological 
distinction (Payne et al., 2004). Further studies of EIAV17 virulence determinants 
propose that SU plays a greater role in virulence than TM (Payne et al., 2004). EIAV17 
containing TM from EIAV19 was shown to cause disease, whereas EIAV17 containing 
SU from EIAV19 resulted in no signs of disease (Payne et al., 2004). The role of SU as a 
virulence determinant is further supported by the up-regulation in mRNA expression of 
IL-1α, IL-1 β, TNF-α, IL-6, and IL-10 during in vitro infection of EMDM by the virulent 
EIAV17 clone, as compared to either EIAV19 (an avirulent clone) or CM (Lim et al., 
2005). 
As further evidence of the role of SU in EIAV virulence determination, 
recombinant SU from virulent EIAV17 (SU17) induced dose-dependent diarrhea similar to 
that reported for SIV SU when administered intraperitoneally to mouse pups (Ball et al., 
2005). Administration of SU17 results in fluid accumulation in mouse intestinal loops 
with no histological lesions, increases in inositol 1,4,5 triphosphate (IP3) levels in HT29 
cells, and induction of chloride secretory currents in Ussing chambers (Ball et al., 2005). 
Dose-dependent diarrhea, similar to enterotoxic peptides from SIV, was also obtained 
using SU17(299-330), an SU17 peptide (Ball et al., 2005). As expected, the administration of 
SU from the avirulent EIAV strain failed to induce a dose-dependent response in mouse 
pups and produced lower levels of activity than SU17 in Ussing chambers and IP3 assays 
(Ball et al., 2005).  
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Because cytokines are expressed at very low levels from EIAV-infected 
macrophages, we chose to use QPCR.  This method is one of the most sensitive and 
accurate methods for measuring cytokine expression in cells (Wang and Brown, 1999; 
Blaschke et al., 2000; Lim et al., 2005; Allen et al., in press).  In order to obtain accurate 
results, the QPCR data were analyzed using relative quantification.  Relative 
quantification differs from absolute quantification in that relative quantification is based 
on the expression levels of a target gene relative to the expression of a reference gene 
rather than to an external calibration curve based on known concentrations (http://docs. 
appliedbiosystems.com/pebiodocs/04303859.pdf, 1997; Pfaffl, 2001; Livak and 
Schmittgen, 2001; Bubner and Baldwin, 2004).  The 18S ribosomal subunit was used as 
the reference gene or “housekeeping gene” to normalize the QPCR results for each target 
gene.  The 18S ribosomal subunit was chosen because it has an amplification efficiency 
of 90%, which is comparable to that of the primers and probes (Allen et al., in press).  
18S also has a very stable cellular concentration that ranges from 1.0-fold to 4.2-fold or 
a difference of 0.5-2.0 Ct values (Schmittgen and Zakrajsek, 2000; Aerts et al., 2004; 
Robinson et al., 2007).  We found that the standard deviation in LPS-stimulated and 
unstimulated cells ranged from 0.58 to 0.81 (Allen et al., in press).  Other housekeeping 
genes such as GAPDH and β-actin were considered, but were found to be too variable in 
cellular expression (Schmittgen and Zakrajsek, 2000; Goidin et al., 2001; Frost and 
Nilsen, 2003; Aerts et al., 2004; Dheda et al., 2004). 
The primer and probe sets for the equine cytokines IL-1α, IL-1β, IL-6, IL-8, and 
TNF-α have been previously validated in Allen et al., (in press) using both standard 
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curves generated from 10-fold dilutions of plasmids encoding the transcript of each gene 
and dilutions of cDNA from LPS-stimulated macrophages.  Non-template samples as 
well as negative RT samples were included in each plate as negative controls, in order to 
detect any evidence of DNA contamination.   
We expected to see small changes in fold induction of cytokines, based on 
previous research by Lim et al., (2005).  Although not statically significant, two of the 
three horses showed the expected increases IL-1α, IL-1β and TNF-α expression after 
treatment with EIAV17, EIAV17SU, and EIAV17TM as compared to treatment with control 
media.  Unexpectedly, we did not see increases IL-6 or IL-8 expression after treatment 
with EIAV17, EIAV17SU, and EIAV17TM as compared to treatment with control media.  
Lim et al., (2005) also observed that IL-6 and IL-8 mRNA expression in EMDM was 
altered by treatment with control media. The upregulation of IL-6 and IL-8 by CM could 
possibly be due to a secreted factor such as prostanoids PGE1 and PGE2, activated 
protein C, or platelet-activating factor (Marshall et al., 1996).   
A recent study involving murine macrophages has shown that the introduction of 
serum factors such as fetal bovine serum and mouse serum into macrophage cultures 
stimulates the production of IL-6 (Brummer et al., in press).  The use of MEMα medium 
supplemented with 10% adult horse serum in the EMDM culture may have complicated 
the measurement of IL-6 production by EMDM. The production of IL-10 by virus 
infected EMDM could also have an effect on IL-6 production.  However, the present 
study did not measure IL-10 expression in EIAV-infected EMDM, Lim et al., (2005) 
reported an increase in IL-10 expression in EMDM infected with EIAV17.  IL-10 is 
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reported to inhibit the production of IL-6 and TNF-α in mast cells stimulated with LPS, 
PGE1 and PGE2 (Marshall et al., 1996).   Control media was processed the same way as 
the media containing the viral clones by the removal of all cell-secreted molecules under 
100 kDa by filtration; but this does not completely exclude the existence of large 
proteins or protein complexes remaining in the control media (Lim et al., 2005).  The 
inclusion of these large proteins or protein complexes in the control media may account 
for the lack of IL-6 and IL-8 expression after treatment with EIAV17, EIAV17SU, and 
EIAV17TM as compared to those treated with control media.   
It is also unclear why two of the horses (A and B) gave the expected trend in 
cytokine induction in EMDM treated with the four clones, but EMDM from the third 
horse (C) treated with the same clones showed little to no cytokine induction relative to 
control media.  This unexpected result could be attributed to individual horse variation. 
In addition, it should be noted that the four EIAV clones were grown in EMDM obtained 
from horse C, and this may have down-regulated cytokine induction in the EMDM from 
horse C.  The incorporation of host cell proteins by lentiviruses into the viral envelope 
can have wide ranging effects on virus life cycle, virus cell interactions, host response to 
virus-incorporated host-proteins, and disease pathogenesis (Cantin et al., 2005; 
Kolegraff, et al., 2006). We speculate that the incorporation of host cell proteins by the 
four EIAV clones could account for the lack of cytokine induction by EMDM obtained 
from horse C.  
In conclusion, when all the data are taken into consideration, there were 
differences in cytokine expression between EMDM treated with the virulent EIAV17 
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clone and those treated the avirulent EIAV19 clone.  Unfortunately, there is no clear cut 
evidence of a difference in cytokine induction between EMDM treated with the 
EIAV17SU clone and those treated the EIAV17TM clone.  More studies need to be done 
using a greater number of horses in order to minimize the impact of horse-to-horse 
variation and perhaps to generate a clearer picture of the differences in cytokine 
induction between the EIAV17SU clone and the EIAV17TM clone. 
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CHAPTER IV 
 
SUMMARY  
 
EIAV is a lentivirus belongs to the family Retroviridae that infects horses, 
donkeys and mules and results in an enduring infection for which there is no remedy 
(Leroux et al., 2004).  EIAV infection does not usually result in death, greater than 90% 
of horses transition to an inapparent or subclinical infection with the horse remaining 
infected for life with EIAV (Montelaro et al., 1993; Harrold et al., 2000).  Because there 
is no vaccine or cure, horses that test positive for EIAV must be euthanized or 
quarantined for life in order to stop the spread of the virus (http://nahms.aphis.usda.gov 
/equine/equine05/equine05_infosheet_eia_trends.pdf, 2006).  EIAV which has a world-
wide distribution has been reduced greatly within the last 35 years, but EIAV has a high 
rate of mutation and the potential to once again become a problem (http://nahms.aphis. 
usda.gov/equine/equine05/equine05_infosheet_eia_trends.pdf, 2006). 
The current study, using QPCR as a method of detection, expanded on previous 
reports based on an equine-specific ribonuclease protection assay (RPA) demonstrating 
differences in cytokine expression between EMDM treated with the virulent EIAV17 
clone and those treated with the avirulent EIAV19 clone.  Although the gag, pol, tat and 
S2 sequences of EIAV17 and EIAV19 are the same, these clones differ in their LTRs, env 
and rev sequences, with the regions of greatest sequence divergence occurring in the 
region of the U3 enhancer and SU (Payne et al., 2004).  Payne et al., (2004) reported that 
both the env and LTR sequences of EIAV17 are required for the acute virulence 
phenotype, when either the env or LTRs of EIAV17 are replaced virulence is eliminated.   
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The env gene is important to virulence because it encodes the SU (gp90) and TM 
(gp45) glycoproteins that are required for virus penetration of host cells and act as potent 
immuno-stimulants (Parekh et al., 1980).  Within the env region, SU is thought to play a 
greater role in virulence than TM, based on results from studies of EIAV17 virulence 
determinants (Payne et al., 2004).  SU has a better ability to stimulate the production of 
antibodies than TM (Leroux et al., 1997).  Based on studies of other lentiviruses, SU 
may interact with ELR1, the cellular receptor for EIAV (Leroux et al., 2004; Ball et al., 
2005; Zhang et al., 2005).  SU also evolves very rapidly during the course of infection 
and recurring disease (Hussain et al., 1987; Payne et al., 1989; Leroux et al., 1997).  Ball 
et al., (2005) reported further evidence of the importance of SU as an EIAV virulence 
determinant when mouse pups injected with recombinant SU protein (SU17) from 
virulent EIAV17 developed dose-dependent diarrhea similar to that reported for SIV SU.  
Lim et al. (2005) also reported significant increases in IL-1α, IL-1β, IL-6, and TNF-α 
expression 0.5 to 1 hpi in EMDM infected with EIAV17 as compared to those infected 
with EIAV19.  This project further extended these studies by examining the effects of SU 
protein on cytokine expression by using chimeric viruses with different combinations of 
SU and TM. 
Two additional chimeric molecular clones, p17Nhe/19/wyoLTR and p19Nhe/17, 
producing viral stocks designated EIAV17SU and EIAV17TM, respectively, were developed 
to investigate the role of the env region in determining the virulence phenotype of 
EIAV17 (Payne, et al., 2004).  To determine if the SU region alone could modulate 
virulence, p17Nhe/19/wyoLTR contains only the SU region from the virulent parent 
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EIAV17, while p19Nhe/17 contains only the TM/Rev region from EIAV17 (Payne, et al., 
2004).  Although EIAV17SU and EIAV17TM have the same gag, pol, tat, S2 and LTR 
sequences as EIAV17, there is a significant difference in the construction of the two 
clones (Payne, et al., 2004).  EIAV17SU shares a segment of the SU region (from amino 
acids 147 to 444) with EIAV17, while EIAV17TM contains the SU region from EIAV19 in 
addition to sharing some overlapping rev sequences and a portion of the TM region 
(from amino acids 20 to 417) with EIAV 17 (Payne, et al., 2004).    
Although EIAV17SU does not seem to be as virulent as EIAV17 it does seem to 
show a greater virulence in ponies than EIAV17TM (Payne et al., 2004).  Shetland ponies 
infected with EIAV17SU experience acute febrile episodes, unlike those infected with 
EIAV17TM, which showed no change in normal body temperature 50 days post-infection 
(Payne, et al., 2004).  Although the infecting dose of EIAV17SU was up to 30-fold greater 
than that of the EIAV17, the severity of resulting febrile episodes was reduced as 
compared  to those previously observed in ponies infected EIAV17 (Payne, et al., 2004).   
Therefore, the virulence phenotype of EIAV17 cannot be attributed solely to the SU 
region, and that the addition of the TM/Rev sequences from EIAV19 may result in 
attenuation of overall virulence (Payne, et al., 2004).  Neither EIAV17SU nor EIAV17TM 
infection resulted acute febrile episodes requiring euthanasia of the ponies in this study, 
although ponies were infected with doses equivalent to or higher than the lethal dose of 
EIAV17 (Payne, et al., 2004).   
In order to expand on these previous studies that used ponies and EMDM,  a set 
of QPCR assays for the detection of equine cytokines IL-1α, IL-1β, IL-6, IL-8 and TNF-
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α were developed and validated.  Primer and probe sets for IL-1α, IL-1β, IL-6, IL-8, 
TNF-α and 18S genes were designed using Applied Biosystems gene expression criteria 
(Allen et al., in press).  First, available nucleotide sequences for each cytokine were 
compared using  GenBank, and those with target regions that were fully conserved, free 
of base ambiguities, and not within alternatively spliced regions were selected and 
submitted to Applied Biosystem’s Assays-by-DesignSM Service for development (Allen 
et al., in press).   
   After the primer and probe pairs were designed and developed, we determined 
the efficiency and reproducibility of the assays.  The equine cytokine QPCR assays were 
evaluated using 5 criteria: 1) the inter-assay variation; 2) the intra-assay variation; 3) the 
variation in RNA extraction and cDNA synthesis; 4) the efficiency of the assays; and, 5) 
the amplification specificity of the assays.  The amplification efficiency, intra-assay and 
inter-assay variation were determined using 10-fold dilutions of plasmid for each gene 
(Allen et al., in press). Under these conditions the amplification efficiencies of the 
primers and probes ranged from 99% to 101% (Table 2.2).  The mean coefficient of 
variation (CV) across five sets of plasmid DNA for both intra-assay and inter-assay 
variation was 0.63% (range 0.2% to 1.8%) (Table 2.3).  Amplification efficiency was 
also determined using 2-fold dilutions of cDNA, and under these conditions 
amplification efficiency ranged from 83% to 95% (Table 2.2). The specificity of 
amplification was confirmed by DNA sequencing of reaction products (Allen et al., in 
press).  The QPCR assays were also evaluated using three sets of cDNA from EMDM 
stimulated for 1 h with LPS (Allen et al., in press).  The general trend was the same for 
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all three samples with IL-1α showing the greatest induction and IL-6 the lowest 
induction (Fig. 2.2).  The range of cytokine induction was greater than has previously 
been reported with values ranging from 12-fold to 30,000-fold (Fig. 2.2).  It was evident 
that the set of QPCR primers and probes were suitable for quantitation of expression 
equine cytokines in EMDM. 
The set of QPCR assays were used to study the effects of EIAV17, EIAV19, 
EIAV17SU, and EIAV17TM on cytokine induction by EMDM.  EMDM from three 
different horse donors was treated with one of the four clones or control media for 1 h.  
The cDNA prepared from the EMDM of the three horses was analyzed using QPCR in 
order to measure IL-1α, IL-1β, IL-6, IL-8, and TNF-α expression.  Overall impressions 
of the data were that cytokine expression levels varied greatly between horses.  EMDM 
exposed to EIAV17, EIAV17SU, and EIAV17TM showed an increase in induction levels in 
IL-1α, IL-1β, and TNF-α expression, but showed a decrease in expression of IL-6 and 
IL-8 (Table 3.1).  Generally, EMDM exposed to EIAV19 showed decrease in IL-1α, IL-
1β, IL-6, IL-8, and TNF-α expression (Fig. 3.2, Fig. 3.3, and Fig. 3.4).  Overall the 
expression of IL-1α by EMDM ranged from 0.49- to 7.21-fold relative to CM (Fig. 3.2, 
Fig. 3.3, and Fig. 3.4).   IL-1β expression ranged from 0.36- to 7.86-fold relative to CM 
(Fig. 3.2, Fig. 3.3, and Fig. 3.4).  TNF-α expression ranges from 0.27- to 4.44-fold 
relative to CM (Fig. 3.2, Fig. 3.3, and Fig. 3.4).  Due to decreased expression in EMDM 
smaller ranges were seen for IL-8 (0.42- to 1.76-fold) and IL-6 (0.03- to 1.22-fold) (Fig. 
3.2, Fig. 3.3, and Fig. 3.4).  It appears that IL-6 and IL-8 expression in EMDM may have 
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been increased by CM treatment, thus lessening the effects of EIAV17, EIAV17SU, and 
EIAV17TM treatment. 
The first part of the hypothesis stated that a positive correlation exists between 
virulence phenotype and increased cytokine expression in macrophages, was supported 
by the data.  The second part of the hypothesis that EIAV17SU would show an increase in 
cytokine induction in EMDM as compared to EIAV17TM, was neither proven nor 
disproven.  The large horse-to-horse variation, combined with a small number of horses 
studied made it impossible to determine if the SU protein alone is responsible for 
modulating EIAV virulence and pathogenesis.  Even with the small number of horses in 
this study, there was evidence of differences in cytokine expression between EMDM 
treated with the virulent EIAV17 clone and those treated with the avirulent EIAV19 clone. 
Perhaps a clearer picture of cytokine induction by EIAV17SU will emerge from future 
studies that include a greater number of horses to offset the large horse-to-horse 
variation in cytokine induction seen in this study. 
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  Fig. 1A. Standard curves used to determine inter-assay efficiency for IL-8 primers and probe.  On the y- 
  axis is the average threshold cycle value for IL-8 and on the x-axis is the log of the copy number for each  
  IL-8 plasmid dilution.  Three separate IL-8 QPCR assays were run on three separate days.  
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  Fig. 2A. Standard curves used to determine inter-assay efficiency for IL-1 alpha primers and probe.  The  
  y-axis is the average threshold cycle value for IL-1alpha and the x-axis is the log of the copy number for  
 each IL-1alpha plasmid dilution. Three separate IL-1alpha QPCR assays were run on three separate days.  
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  Fig. 3A. Standard curves used to determine inter-assay efficiency for IL-1 beta primers and probe.  The 
  y-axis is the average threshold cycle value for IL-1beta and the x-axis is the log of the copy number for  
  each IL-1beta plasmid dilution. Three separate IL-1beta QPCR assays were run on three separate days.  
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 Fig. 4A. Standard curves used to determine inter-assay efficiency for TNF-alpha primers and probe.  The 
y-axis is the average threshold cycle value for TNF-alpha and the x-axis is the log of the copy number for 
each TNF-alpha plasmid dilution. Three separate TNF-alpha QPCR assays were run on three separate 
days.  
 103
 
IL-8 plasmid intra-assay variability 5-12-05
y = -3.4139x + 37.749
R2 = 0.999
0
10
20
30
40
0.00 2.00 4.00 6.00
Log of copy number
Av
er
ag
e 
Ct
 v
al
ue
Average IL-8 Ct
Linear (Average
IL-8 Ct)
  Fig. 5A. Standard curve used to determine intra-assay efficiency for IL-8 primers and probe.  A single 
  IL-8 QCPR assay was performed using 10 replicates of each of the following plasmid copy numbers 1 x 
  105, 1x 103, 1 x 102, and 1 x101. 
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  Fig. 6A. Standard curve used to determine intra-assay efficiency for IL-1 alpha primers and probe.  A  
  single IL-1 alpha QPCR assay was performed using 10 replicates of each of the following  plasmid copy 
  numbers 1 x 105, 1x 103, 1 x 102, and 1 x101. 
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 Fig. 7A. Standard curve used to determine intra-assay efficiency for IL-1 beta primers and probe.  A  
 single IL-1 beta QPCR assay was performed using 10 replicates of each of the following plasmid copy  
 numbers 1 x 105, 1x 103, 1 x 102, and 1 x101. 
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  Fig. 8A. Standard curve used to determine intra-assay efficiency for TNF-alpha primers and probe.  A  
  single TNF-alpha QPCR assay was performed using 10 replicates of each of the following plasmid copy 
  numbers 1 x 105, 1x 103, 1 x 102, and 1 x101. 
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